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Abstract 
 
Background 
Diabetic patient's numbers are increasing around the world, this metabolic disease affects 
patient's quality of life in all domains: physically, socially, psychologically and 
emotionally. As the disease progresses patients need to use insulin. According to the 
Palestinian MOH 12% of people in Palestine have diabetes. Twenty percent of type 2 
diabetic patients, visits the MOH clinics, use insulin and 12% use both insulin and oral 
drugs to control their blood glucose levels. The only choice for these patients is the use of 
syringe and vial for the administration of insulin. Most of the diabetic patients QoL studies 
have been conducted in developed countries and only a few in developing countries.  
Objective 
The aim of this study was to assess QOL of diabetic patients using insulin and factors 
affecting it. 
Method 
A cross sectional study conducted on a sample of 311 diabetic patients using vial/syringe 
to administer insulin and attending MOH diabetic clinics in Bethlehem and Hebron. The 
questionnaire used was four parts; socio-demographic part, patient's health profile, QOL 
part and willingness to pay for insulin pens part. QoL measured using SF-36v2® 
questionnaire and the willingness to pay part validated using pilot study. The MOH 
approved the study and a verbal patient’s consent obtained. Results were analyzed using 
QualityMetric Health Outcomes™ Scoring Software 4.0 and SPSS software.  
Results and conclusion 
The mean scores of QoL domains ranges from 40.7 to 65.6. The domain with the highest 
score was social functioning (M = 65.6), followed by physical functioning (M= 58.91) and 
role emotional (M = 58.91) while the lowest was vitality (M = 40.7). Diabetic patients in 
this study had lower scores than general population in all domains of QoL; Physical 
Functioning, Role-Physical, Body Pain, General Health, Vitality, Role-emotional, Mental 
Health, physical composite summary and mental composite summary, except in social 
functioning. The majority of participants had lower scores than general population. 
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 The result revealed that gender, age and glycemic control had no significant impact on 
QoL. Married patients had better QOL than other patients. On the other hand it was 
influenced by residency, marital status, level of education, employment, monthly income, 
diabetes duration, diabetes type, diabetes complications and insulin regimen. 85% of 
participants preferred to use insulin pens if it was available as a choice in the MOH, and 
35% of them were willing to pay extra money to get insulin pens instead of vial/syringe.  
This study revealed that QoL of diabetic patients use insulin is low, which can be increased 
if the government included insulin pens in the MOH dug list, since many studies revealed 
that the use of insulin pens increases the QoL.   
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Chapter 1: Introduction 
 
1.1 Diabetes 
 
Diabetes is a metabolic disease characterized by hyperglycemia, caused by 
deficiency in insulin secretion or tissue resistance to insulin action. 5-10% of diabetic 
patients have type 1 diabetes that is caused by destruction of B cells of the pancreas.  90-
95% of patients have type 2, which is caused by insulin resistance and deficiency. Other 
types include gestational diabetes mellitus, diabetes due to genetic defects in B cells or 
insulin action and chemical or drug induced diabetes. The criteria for the diagnosis of 
diabetes is hemoglobin A1c (HbA1c) 6.5 or fasting blood glucose   126 or 2 hours 
plasma glucose  200 using 75g glucose tolerance test, while type 1 diabetes is diagnosed 
when the patient appears with acute hyperglycemia.  
Diabetes is related to microvascular and macrovascular complications. 
Microvascular complications include retinopathy, nephropathy and peripheral neuropathy, 
macrovascular complications include CVD, which is the most common cause of death in 
diabetic patients. Type 2 diabetes is frequently undiagnosed till the patient suffers from 
complications. Treatment of type 1 requires multiple daily insulin injections, type 2 
treatment starts with oral hypoglycemic drugs and insulin is used at a later stage once 
blood glucose is no longer controlled by oral hypoglycemic agents. Glycemic control is the 
goal of treatments and lowering HbA1c to below 7% is the goal of treatment that is known 
to reduce diabetes complications (Association, 2005, 2012).  
1.2 Epidemiology of diabetes 
 
The number of diabetic patients is increasing due to the increase in population age, 
obesity, rapid urbanization, physical inactivity and lifestyle changes.  Many studies 
estimated the prevalence of diabetes in the future extrapolated from the current prevalence 
around the world. King et.al study (Kinge, Aubert, & Herman, 1998) suggested that 
between 1995 and 2025 the prevalence of diabetes will be increased by 35% and the 
number of diabetic patients by 122% from 135 million in 1995 to 300 million in 2025.  
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The number of people with diabetes in year 2000 was also estimated by Wild et al. 
(Sarah, Gojka, Anders, Richard, & Hilary, 2004) to be 171 million, which is higher than 
what was expected by King et. al., this study estimated the prevalence of diabetes to be 
doubled between 2000 and 2030. Both studies estimated the number of people with 
diabetes to be higher in developed countries than developing, and higher in urban than in 
rural. 
 Another study estimated the prevalence of diabetes worldwide for 2010 and 2030 
using 133 studies from 91 countries found that; the highest prevalence for 2010 was in 
North America followed by Middle East and South Asia. By 2030 African countries are 
expected to have the highest prevalence followed by Middle East and North America. 
From 2010 to 2030 the overall increase in diabetics numbers is predicted to increase by 
54%, number of diabetic patients in developing countries is expected to increase by 69%, 
while in developed countries by 20% (Shaw, Sicree, & Zimmet, 2010).   
1.3 Diabetes in Palestine    
 
In Palestine one in ten people and two thirds of those older than 60 have at least 
one chronic disease (Husseini, Abu-Rmeileh, & Mikki, 2009). Husseini et.al. investigated 
the prevalence of diabetes in rural Palestinian population in Kobar, a village near 
Ramallah.  The study included 500 participants, it was found that the prevalence of 
diabetes was 9.6%, which is considered high specially that the percentage is expected to be 
higher in urban areas (Husseini, 2000).  
A recent publication from Birzeit University indicated that the prevalence of 
diabetes in Palestine was 15.3%  in 2010 and is expected to increase to 23.4% by 2030 
(Abu-Rmeileh et al., 2017). 
According to the Palestinian MOH; 12% of people in Palestine have diabetes, 
which is estimated to be 500,000 patients. 5% of these patients have type 1 diabetes. On 
the other hand, 61% of type 2 diabetic patients use oral hypoglycemic drugs, 20% use 
insulin and 13% use both insulin and oral drugs to control their blood glucose levels. In the 
annual report 2016 there was 5761 new diabetic patients registered in the MOH. The 
number of patients visits the MOH facilities is 148,508 and 54,652 of them have diabetes 
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complications. The number of deaths caused by diabetes complications was 869 in 2015, 
which is estimated to be 19.7 out of 100.000  (Health Report, 2016).  
1.4 Quality of life 
 
QoL is a personal evaluation of how good or bad their life is. It evaluates the 
satisfaction of person's life in many aspects including psychological, environmental, social 
and physical. HRQoL concerns of health aspects as well as general QoL; it is the patient's 
perception of the effect of illness or treatments on their QoL, these two concepts, QoL and 
HRQoL, are used interchangeable (Theofilou, 2013). 
QoL was defined by the WHO in 1947 as the perception of the individual's position 
in life, including the person's satisfaction of physical health, psychological health and 
social relationships. QoL is subjective; each person thinks of specific dimensions when 
he/she wants to evaluate their life, it also changes over time and influenced by many 
effects (Speight, Reaney, & Barnard, 2009; Theofilou, 2013).   
 
1.5 QOL measurements 
 
Only in recent years there has been a great interest in QoL measurement. In the first 
measurement depended on factors like physical symptoms, anxiety and depression or 
ability to attend to school. It is used in clinical trials especially for chronic diseases in order 
to measure improvements in patient's feeling and daily functioning.  
QoL measurement could be done using generic measures or disease specific 
measures. Disease specific measures provide detailed information about the disease and 
treatment care impact on QoL while generic instruments assess the more global effect of 
the disease and complications on quality of life. Diabetes specific measurements contain 
domains that are specific for diabetic patients such as diet and enjoyment of food. diabetes 
specific instruments include Diabetes Quality of Life, Diabetes-39, Problem Areas in 
Diabetes (PAID) survey, Audit of Diabetes-Dependent Quality of Life (ADDQOL) and 
Diabetes Specific Quality of Life (Rubin & Peyrot, 1999; Speight et al., 2009) .  
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Generic measures such as the World Health Organization Quality of Life - Brief 
(WHOQOL-BREF) and The European Quality of Life (EUROQOL) are preferred by many 
scientists because they are more concerned about psychosocial factors. These instruments 
assess concepts that are relevant to everyone. The choice of the questionnaire depends on 
the purpose of the research, the time for the completion of the questionnaire and possibility 
of self-administration (Eiser, 2004; Theofilou, 2013).  
1.6 SF36 
Short-form survey (SF-36) is a short health survey with 36 questions. It was 
introduced in 1980, constructed by the Medical Outcomes Study (MOS). This survey has 
been used as a QoL measurement in general and specific population. The most frequently 
studied diseases used SF36 as QoL measurement tool are arthritis, back pain, diabetes, 
hypertension and depression (Ware Jr, 2000; Ware Jr & Sherbourne, 1992).     
It includes eight health concepts (Figure 1): 1- Physical Functioning; this part 
includes questions such as climbing stairs, kneeling and walking, 2- Role Physical; 
limitations because of physical functioning, 3- pain; questions are concerned of pain that 
interfere with daily activities, 4- Social Functioning; this part contains questions about the 
effect of physical and emotional health on social life, 5- Mental Health that includes 
anxiety, depression and behavioral control, 6- Role Emotional, 7- Vitality, which includes 
energy and fatigue and 8-general health. It also includes physical and mental health 
summary that are formed from the eight domains. Studies have shown that the 
questionnaire domains are valid and reliable (Ware Jr, 2000).  
Summary 
measures 
Scales Items 
 
 
 
 
 
 
 
 
 
Physical    
functions 
(PF) 
Moderate activity 
Lift, carry grocery 
Climb several flights 
Climb one flight 
Bend, kneel 
Walk mile 
Walk several blocks 
 
Walk one block 
Bathe, dress 
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Physical 
Health 
(PCS) 
 
 
 
 
 
 
 
 
Role 
physical 
(RP) 
Cut down time 
Accomplished less 
Limited in kind 
Had difficulty 
Bodily 
pain 
(BP) 
Pain magnitude 
Pain –interfere 
 
General Health 
(GH) 
EVGFP rating "In general would you 
say your health" 
Sick easier 
As healthy 
Health to get worse 
Health excellent 
 
 
 
 
 
 
Mental 
Health 
(MCS) 
 
 
Vitality 
(VT) 
life 
Energy 
Worn out 
Tired 
 Social    
Functioning 
(SF) 
Social extent 
Social time 
Cut down time 
Role 
Emotional 
 (RE) 
Accomplished less 
Not careful 
 
Mental 
Health 
(MH) 
Nervous 
Down in dumps 
Peaceful 
Blue/sad 
Happy 
 
Figure 1: SF-36 health concepts. 
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 This survey can be self-administered, computerized administration, phone-
administration or personal interview to persons older than 14 years. This survey is short 
and can be administered in 10-15 minutes. Each domain is scored from 0 to 100 with a 
mean of 50 and a standard deviation of 10, scores less than 50 (average) represents health 
status below average. Results also are interpreted as norm based scoring (Ware Jr, 2000; 
Ware Jr & Sherbourne, 1992).  
In a study to examine the use of SF-36 generic survey and the Audit of Diabetes 
Dependent Quality of Life (ADDQOL) in QoL evaluation for diabetic patients, it was 
found that the use of generic and disease specific measure together was complementary. 
Diabetes related comorbidities were detected by the two surveys while SF36 was strongly 
affected by non-diabetic comorbidities (Woodcock, Julious, Kinmonth, & Campbell, 
2001).   
Another study compared SF-36 and DCP (Diabetes Care Profile), a diabetes 
specific survey, in patients with type 2 diabetes. It was found that either or both 
instruments can be used to measure QoL in diabetic patients depending on the purpose of 
the study. Both instruments were highly reliable and provided valid information about 
patients with diabetes (Anderson, Fitzgerald, Wisdom, Davis, & Hiss, 1997).  
1.7 Pharmacists and QOL 
Pharmacists have an important role in diabetes management  with the increase in 
diabetes regimens complexity. Many studies studied the role of pharmacists on diabetic 
patients QOL. Pharmacists role included counseling and education on diabetes, 
medications, lifestyle changes, medication adherence and drug related problems. Most of 
these studies found that QOL was improved with pharmacists intervention (Pousinho, 
Morgado, Falcão, & Alves, 2016; Wubben & Vivian, 2008).  
1.8 Willingness to pay 
 
Willingness to pay is the maximum amount of money that the individual would pay 
to get the benefits of a service or intervention. WTP will be different between patients 
depending on the preferences and income. In order for healthcare decision makers to 
determine to reimburse a certain intervention or treatment the incremental benefits are 
found, the incremental benefits are the sum that each patient is willing to pay; if the 
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incremental benefits are higher than the incremental costs then the treatment is preferred 
(Bala, Mauskopf, & Wood, 1999). 
WTP studies are used to examine the impotence of certain treatment attributes for 
the patients by allowing them to choose between two hypothetical products' profiles and 
explore the patient's preference and the out of pocket money they will trade for these 
attributes.   
1.9 Problem statement 
 
A large number of studies have been conducted to characterize HRQOL in diabetic 
patients. Caring for those patients is a global challenge with the increasing in the number 
of people living with diabetes. They make a huge effort and many decisions every day and 
all day long to reach a non-diabetic metabolism rate, which will affect social, physical and 
emotional aspects of life. So the evaluation of QoL in these patients is essential to measure 
psychosocial well-being, the benefits of new treatments and identify the dissatisfaction of 
the existing treatments. Many studies found that the association of complications with 
diabetes such as cardiovascular disease and neuropathy decreases quality of life and 
increases depression and anxiety (E. S. Huang, Brown, Ewigman, Foley, & Meltzer, 2007).   
Diabetic patients face daily obstacles in order to achieve glycemic control; they 
need blood glucose monitoring, diet changes, medical visits and adherence to the drugs, 
which affects their QoL. Most of the diabetic patients QoL studies have been conducted in 
developed countries and only a few in developing countries.  
Diabetic patients who cannot control blood glucose using oral hypoglycemic drugs 
need to use insulin in order to decrease HbA1c.  In order to achieve glycemic control 
multiple daily injections of insulin are recommended for patients. Many patients treated 
with insulin fear the needles, may lack sufficient diabetes education and deny the need for 
insulin, all these reasons contribute to the non-adherence in those patients (Asamoah, 2008; 
Control & Group, 1993),  
In 2012 a study was performed in Al-Makhfia governmental diabetes primary 
healthcare clinic in Nablus city to assess medication adherence in patients with type 2 
diabetes; the Morisky Medication Adherence Scale (MMAS-8) was used as the adherence 
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measurement tool. It was found that 57.3% of patients were considered adherent and 
42.7% were non-adherent. 17% of patients reported that they stopped taking their medicine 
because they felt worse upon taking them, 33% of patients reported that they forgot to take 
their medication when they left home, 34.6% reported that they are annoyed by their 
treatment plan. In this study it was shown that non-adherence was associated with diabetes 
knowledge, concerns about medication side effects and believes about the necessity of the 
treatment (Sweileh et al., 2014).  
In 2011 a study was performed in Ramallah to assess the level of glycemic control 
in patients with type 2 diabetes in Ramallah governmental clinics. 517 patients participated 
in the study, the mean HbA1C was 8.8%. The majority of patients had poor glycemic 
control and only one in five patients achieved glycemic control. The percentage of patients 
with poor glycemic control among patients used insulin or a combination of insulin and 
oral drugs was higher than patients use oral drugs alone or patients used no drugs. It was 
found that patients who have diabetes for less than 7 years are more likely to have a 
controlled glycemic sugar than patients who have diabetes for more than 7 years (Imseeh, 
2013).  
The main objective of the study described in this thesis is to evaluate the QoL of 
diabetic patients that use insulin in order to understand how diabetes and it's complications 
in this patient population affects patient's life. This study will identify important variables 
that affect QOL for these patients.    
Non-adherence leads to poor glycemic control and the development of diabetes 
complications such as retinopathy and nephropathy (Asamoah, 2008; Control & Group, 
1993). A large part of the health care budget of diabetes is used to treat diabetes 
complications, those complications can be significantly reduced if the patients have 
controlled their blood glucose (Stockl et al., 2007). 
In order to estimate medical costs of diabetes in 2010 and future costs in 2030 a 
study was performed in Palestine by Niveen Abu-Rmeileh and her colleagues (Abu-
Rmeileh et al., 2017). Direct costs were estimated to be $194 million in 2010, these costs 
are expected to increase to 316 million in 2030. When diabetes complications are included, 
the cost tripled and estimated to be $341 million in 2010 and increase to $567 million by 
2030. Diabetes costs are estimated to take 11.9% - 15.4% of the total health expenses from 
2012 – 2030.  
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In order for patients to adhere to the insulin regimen, the insulin needs to be easy to 
use, minimize lifestyle disruptions and the ability of patients to learn the skills to use the 
insulin delivery system such as insulin pens. The simplicity of insulin pens will improve 
the compliance of patients and is especially important for older patients and patients 
having a difficulty in handling injection devices. Patients with low income should be 
encouraged to use devices such as insulin pens, in spite of their initial higher costs, in order 
to reduce health care resources costs including prescription costs, diabetes related health 
care costs and outpatient costs (Pawaskar et al., 2007).  
In the Ministry of Health in Palestine the vial/syringes are available for insulin 
delivery and not insulin pens, in this study we will use a willingness to pay survey in order 
to examine the preference of patients for insulin pens. 
1.10 Specific objectives  
1. To assess the perceived QoL among diabetic patients using insulin and visiting 
MOH facilities in Bethlehem and Hebron.  
2. To assess whether or not the QoL measure is related to socioeconomic status of 
diabetic patients.  
3. To correlate the relationship between duration of the disease and the   patient's 
QoL.  
4. To examine the association between the QoL and DM complications.  
5. To assess the preference of diabetic patients for insulin pens and the amount of 
money they are willing to pay for them.  
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Chapter 2: Literature review 
2.1 QOL and diabetes 
Some studies found that patients taking oral medications have a better QoL than 
those that use insulin while others found no significant association between treatment 
regimen and QoL. Most studies found a relationship between glycemic control and QoL. 
Generally QoL is lower in diabetic patients than other people. On the other hand diabetic 
patients have better QoL than people with other chronic diseases such as cardiac problems, 
arthritis, epilepsy and stroke, except for hypertension. Many studies found that QoL of 
diabetic patients can be improved by educational and counseling programs, introductions 
of new drugs and the change in insulin delivery systems (Rubin & Peyrot, 1999). 
Glasgow et al. (Glasgow, Ruggiero, Eakin, Dryfoos, & Chobanian, 1997) evaluated 
quality of life in 2800 diabetes patients of type 1 and 2 in the U.S using the Medical 
Outcomes Study (MOS) Short-Form (SF)-20. They found that diabetic patients in this 
study had lower quality of life than other population, men had higher quality of life than 
women, patients with lower income had lower quality of life and patients of type 2 diabetes 
taking insulin had lower quality of life than other patients. 
Diabetic patient's quality of life was measured in Saudi Arabia using hospital 
anxiety and depression scale (HADS) and SF-36 survey. This study found that women and 
patients older than 50 had lower QoL, patients with higher income had higher QoL, 
patients using insulin had lower QoL than patients using other combination regimens 
including oral hypoglycemic agents and insulin, also the longer duration of diabetes was 
associated with lower QoL (Al Hayek, Robert, Al Saeed, Alzaid, & Al Sabaan, 2014).  
A study conducted in 2012 in China using the diabetes-specific quality of life 
(DSQOL) questionnaire and the Zung Self-rating Depression Scale (ZSDS), they found 
that QoL was lower in patients have neuropathy, coronary heart disease (CHD), 
microvascular complications, peripheral vascular disease (PVD) and depression. On the 
other hand regular exercise was associated with higher quality of life. QoL was not 
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affected by HbA1c, while patients that regularly attend diabetes education had a higher 
quality of life (Cong, Zhao, Xu, Zhong, & Xing, 2012).  
In 2006 a HRQOL study of diabetic patients was conducted in the refugee camps in 
Gaza strip, a sample of 200 diabetic and 200 non-diabetics was recruited to examine QoL. 
The World Health Organization Quality of Life Questionnaire – short version (WHOQOL-
BREF) was translated to Arabic and used. 80 % of these patients had complications such as 
diabetic foot, neuropathy and nephropathy; more than 50% of them used oral medications. 
It was found that diabetic patients had lower income education and widowed compared to 
non-diabetics. WHOQOL involves physical, psychological, environmental and social 
relationships and in all these domains diabetic patients had lower scores than non-
diabetics. In the controls there was no difference between males and female and between 
older and younger than 50 in QoL, while in diabetics females and older patients had lower 
QoL (Eljedi, Mikolajczyk, Kraemer, & Laaser, 2006).  
In order to evaluate patient's perception of quality of life and their relationship with 
diabetes complications and treatments a study was performed in 2007 in Chicago area 
clinics. 23% of patients reported they had experienced microvascular complication and 
30% reported that they have cardiovascular complications. 61% of the patients in this study 
used oral drugs, 25% used insulin and 14% use no medication to control their blood 
glucose. Regarding treatments the lowest quality of life ratings were for patients use 
multiple daily injections of insulin while these ratings were not significantly different for 
patients used comprehensive oral medications. Patients reported quality of life with 
complications to be significantly lower than that without diabetes complications (E. S. 
Huang et al., 2007).  
 A study was conducted in the North of West Bank to measure the QoL in patients 
with type 2 diabetes using SF-36 questionnaire. The study found that 30% of patients have 
poor general health and moderate pain; diabetic patients in general have poor functional 
activities. It was also found that women have poor QoL compared to men, patients with 
high level of education have better QoL than patients with low level of education and older 
patients have lower QoL than younger patients (Showli, 2013). 
In 2011, a study to measure the QoL using SF-36 with diabetes type 1 patients was 
performed in the northern districts in the West Bank using patients registered in the MOH 
facilities. The mean score of QoL ranged from 51.7% to 75.6%, the highest scores were in 
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the bodily pain domain and the lowest in general health domain. Those results were lower 
than QoL of type 1 diabetes in other populations. The presence of complications was the 
most dominant variable that affected QoL negatively. It was also found that the level of 
education, the presence of additional source of family income and body mass index were 
negatively associated with QoL. Physical activity was associated with better QoL, high 
level of HbA1c was associated with low QoL scores and the increase in number of insulin 
injections per day negatively affected QoL (Alkarmi, 2013). 
 
2.2 Psychological insulin resistance 
 
Eventually and because of the progressive nature of diabetic type 2 patients will use 
insulin in order to control glucose levels. But most patients experience anxiety about 
insulin injections, which form a barrier for physicians who needs to start insulin treatments 
(Funnell, 2008). 
 
Many studies identified patient's barriers for insulin use which included; the fear 
that they would lose control on their lives, the feeling of failure to control their blood 
glucose, believing that insulin will affect their social relationships, anxiety about insulin 
injections, the fear of insulin side effects and the fear that they couldn't manage insulin 
therapy requirements (Funnell, 2008). 
The DAWN study examined patient and provider attitude toward insulin therapy in 
13 countries, the results suggested that believes about insulin among providers related to 
cultural factors and health care systems. They found that many providers do not believe 
that insulin can reduce the costs of diabetes care and the delay in insulin therapy was 
significantly less among providers who believed insulin was efficacious. Regarding 
patients they found that patients in a more distress situations such as more complications 
and worse control have a stronger believe that insulin is efficacious  (Peyrot et al., 2005). 
Insulin naive patients resist and delay insulin therapy, which extends periods of 
hyperglycemia and leads to diabetes complications, this resistance is due to the believe that 
using insulin indicates loss of control over patient's life, the loss of confidence that they 
can be qualified to use insulin, the believe that insulin use indicates personal failure and the 
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disease itself is more dangerous now, anxiety due to the self-injections and they don't 
believe that insulin will help them (Polonsky & Jackson, 2004). 
2.3 Pens vs. vial use 
 
The traditional insulin injections are time consuming and painful. The insulin pen 
device contains the insulin vial and the syringe together in a small size pen. Insulin pens 
are either prefilled or reusable pens. Prefilled pens contains a built in insulin cartridge, 
which makes it easy for the patient to use but it is more expensive. The reusable pen's 
cartridge can be changed, which allowed patients to use more than one type of insulin in 
the same pen, it is more economical than prefilled pens. To use the pen, the disposable 
needle is screwed into the pen, the dose is selected by the patient from the display window 
then the hidden needle is placed on the site of administration and when the injection button 
is pressed, the subcutaneous dose is delivered. Before usage the pen should be stored in the 
refrigerator, after usage it can be kept at room temperature for a month. Pens needles are 
shorter and thinner than the standard syringe needle, which reduces the pain at the time of 
injection. Air bubbles in insulin syringes leads to inaccurate dose, which can be a problem 
for patients with vision problems so the use of insulin pens can be beneficial for those 
patients (Bohannon, 1999). 
Starting insulin therapy is easier with pens since they are easier to teach compared 
to vials, dose accuracy is more in using pens, they are also more socially accepted, can be 
used discreetly, easier to be used in older patients with disabilities, and they  cause less 
pain. Pens cost higher than injections but compliance of patients leads to a decrease in the 
overall health care  resources use (Asamoah, 2008). 
In order to compare insulin pens with syringes, Cliff Molife et. al (Molife, Lee, Shi, 
Sawhney, & Lenox, 2009) reviewed patient's reported outcomes in articles published 
between 1980 to 2008, this review demonstrated that the majority of patients using pens 
reported less pain, higher treatment satisfaction, more convenient, easier to use, quicker, 
more socially accepted  than patients using vial and syringes. All these findings suggested 
that the use of insulin pens will increase adherence and glycemic control. 
In 1989 a study was performed to assess the use of NOVOLIN prefilled disposable 
and durable pens use compared to the use of insulin vial and syringe. 79% of patients 
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preferred the use of Novolin prefilled pen compared to 7% who preferred vial and syringe. 
93% of patients reported that it was easy to take insulin using Novolin pen compared to 
38% reported the same using vial/syringe and 75% of patients reported that the use of pen 
had a positive effect on their overall wellbeing compared to 47% reported such effect using 
vials.  On the other hand, according to the patients used Novopen 1.5 durable pen 98% of 
them reported that it was easy to use it and 86% indicated that the use of it was easier than 
the use of vials.  85 % of patients rated the pen more comfortable than syringe/vial and 
97% planned to continue using Novopen 1.5. Patients used prefilled pen in this study 
reported that they felt more confident about management of diabetes and patients used 
durable pen reported that it was easier to comply to treatment regimen, which suggests that 
the use of pens may help patients to adhere to their insulin treatment regimens, which will 
decrease long-term complications (Graff & McClanahan, 1998). 
A study was performed between January 1, 2009, and December 31, 2010 to 
compare the adherence between patients using vial/syringe and prefilled pen. This study 
showed that compliance was similar between patients using vial/syringe and pens, while 
the persistent with insulin therapy was more in patients used prefilled insulin over the 24 
months of the study (Cheen, Lim, Huang, Bee, & Wee, 2014). 
 
Pawaskar et.al (Pawaskar et al., 2007) studied economic outcomes, health resource 
utilization and adherence in patients of type 2 diabetes, they compared between patients 
who initiated insulin using vials verses patients using pens and between patients using 
vials/syringes converted to pens verses patients continued to use vials/syringes, all these 
patients were followed for 24 months.  Patients initiated insulin therapy using pens had 
lower overall health costs compared to vials users, this decrease was due to lower insulin 
prescription costs, lower total hospital costs and lower total outpatients visits. For patients 
who switched to pens, the costs were comparable with who stayed on syringes, but there 
was a cost reduction in syringe related resource expenses use in patients converted to pens.  
This study demonstrated that in spite of the higher costs of insulin pens there is a reduction 
in the overall health care costs.  
2.4 Patient's preference for insulin pens 
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In order to assess patients preference of insulin devices (pens over vial/syringe) and 
to examine glucose control a cross over study was performed in USA for patients of type 1 
and 2 diabetes for twelve weeks, all patients were using insulin vials and naive to pens. 
Seventy four percent of patients preferred insulin pens, while twenty percent only preferred 
syringes; the results also showed that there was no significant difference in the glycemic 
control profiles. 85% of patients reported that reading the dose scale was easier using pens 
and 73% felt more confident in the accuracy of insulin dose using pens compared to 
syringes. 85% of patients reported that the use of pens was more discrete to be used in 
public places, 74% indicated that the use of pens is easier than syringes. During this study 
two serious hypoglycemic adverse effects were reported during the use of syringe/vial 
while none were reported during pens use (Korytkowski, Bell, Jacobsen, Suwannasari, & 
Team, 2003).  
Stockle et.al (Stockl et al., 2007) studied the preference of patients of insulin 
delivery system, disposable prefilled doser that is similar to insulin pen, or vial/syringe. 
260 patients were enrolled; all patients were using insulin via vial/syringe method, have 
diabetes type 1 or 2. 71.5% of patients reported the preference for disposable doser. 
Patients also reported that the use of disposable doser was easier to administer insulin, 
more convenient, more comfortable to be used in public places, made their life easier, 
allowed them to have a more enjoyable social life and provided a better quality of life. 
After using the disposable doser patients reported a decrease in fear of self-injection, a 
higher insulin treatment satisfaction, more lifestyle flexibility, less time for insulin 
administration, less often missed doses and better glycemic control than after using 
vial/syringe. The use of vial/syringe was associated with a lower compliance and more 
injection pain compared to the use of disposable doser.  
2.5 Insulin pens and QoL 
 
In order to examine if the QoL would improves by the use of insulin pens 72 
insulin dependent patients were studied in Sweden. These patients moved from injections 
to pens, after 9-13 months of the introduction of insulin pens the majority of patients 
reported QoL improvement. The items with highest mean change were alleviation of 
discomfort from the diabetes, increased stability in the disease, fewer episodes of 
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hypoglycemia, enhanced general well-being and the ability to lead an active life 
(Hörnquist, Wikby, Andersson, & Dufva, 1990). 
 
2.6 Willingness to pay in diabetes studies 
 
Willingness to pay for treatment improvements was studied in Sweden with type 2 
diabetic patients; participants were willing to pay a considerable amount of money each 
month to improve their treatment and gain health benefits. The most important aspects for 
patients were gaining weight, prevention of hypoglycemia and reduce HbA1c (Jendle et al., 
2010). 
A study was conducted to examine the willingness to pay of diabetic patients using 
insulin for attributes of long acting insulin therapy. Subjects were willing to pay a 
substantial amount of money to improve their treatment and the most important attributes 
for them were avoiding weight gain, easiness of using insulin device, avoiding 
hypoglycemia and reduction of number of injections per day (Lloyd et al., 2011).  
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Chapter 3: Methods 
 
This was a cross sectional study among diabetic patients that use insulin in 
Bethlehem and Hebron MOH clinics. Cross sectional study allows the collection of large 
amount of data from a population in a short period of time using a questionnaire. Cross 
sectional studies are the best to determine the prevalence of the outcome of interest in a 
population, identifying associations and allow studying multiple outcomes at one point in 
time only, these studies are done in short time and with limited resources (Levin, 2006; 
Mann, 2003).  
3.1 Study instrument 
In our study we used a questionnaire of three parts; socio-demographic, quality of 
life and willingness to pay. 
3.1.1 Socio-demographic sheet 
The socio-demographic information sheet ( 
Appendix A) covered the following areas of interest:  Gender, age, educational level, 
marital status, residency and income status.  
3.1.2 Health profile 
 
Health profile part included duration of DM, duration of insulin use, type of diabetes, 
information about the use of insulin syringes, HbA1c level, type of treatment, incidence of 
hypoglycemia, insulin dosage regimen and presence of complications. 
3.1.3 Quality of life (SF-36 questionnaire)  
 
In this study, the Palestinian version of SF-36v2® (Appendix B) Health Survey 
was used to assess quality of life for diabetic patients using insulin. The Non-Commercial 
License Agreement was obtained from OptumInsight Life Sciences incorporation 
(OPTUM). SF-36v2 is a valid survey that has been used in many studies. The certificate of 
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Arabic (for Palestine) of the SF-36v2® Health Survey was obtained from the OPTUM 
incorporation (
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Appendix D).  
We used the eight domains measured by SF-36; physical functioning (PF), role 
physical (RP) which is role limitation due to physical health issues, bodily pain (BP), 
general health (GH), vitality and energy (VT), social functioning (SF), role emotional (RE) 
that is role limitation due to emotional problems and mental health (MH) to assess quality 
of life. Also the two summary components were used that are 1- physical component 
summary (PCS), which represents physical limitations, disabilities and the presence of 
fatigue and body pain. 2- The mental component summary (MCS), which evaluates 
psychological distress and limitations due to emotional problems.  
The scoring range of the eight scales ranges is from 0 to 100, higher scores 
indicates a better quality of life. This version of SF36 includes norm-based scoring, each of 
the eight domains and the two summary measures is scored to have a mean of 50 and 
standard deviation of 10, which allows the comparison with general population. When the 
scores are above the score at the upper end of the 95% confidence interval it is considered 
above the general population t-score and when the patient score is below the score at the 
lower end of the confidence interval it is considered below the general population t-score.      
 
3.1.4 Willingness to pay survey (WTP): 
 
WTP survey ( 
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Appendix C) was used in this study to examine the patient's preference for the insulin pens 
and their willingness to pay for those pens. 
WTP questions are either closed-ended question, in which the patients are asked if they would 
pay a specific amount of money for the health service the answer will be yes or no, or open ended 
question, in which the patients can be asked what is the maximum amount they are willing to pay 
or a payment scale can be used, in which the patients are presented with a scale of possible WTP 
values (Donaldson, Jones, Mapp, & Olson, 1998).  In this study a payment scale was used in order 
to ask about the amount of money the patient is willing to pay for the insulin pens. 
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3.2 Population and sampling 
 
3.2.1 Study population 
 
The target population for this study was diabetic patients that use insulin by 
vial/syringe and attend the MOH clinics in Bethlehem and Hebron. MOH facilities have 
purposely chosen based on the high percentage of diabetic patients attending these health 
care facilities. In Bethlehem; the central, Maskat, Beit Jala and Beit Sahour clinics were 
chosen. In Hebron Halhoul, Karanteena and diabetes center in Doora clinics were chosen. 
Selection criteria  
Inclusion criteria  
 Diabetic patients use insulin by vial/syringe.  
 Age 17 years and more (both male and female).  
Exclusion criteria  
 Patients who did not agree to participate.  
 Patients use only oral hypoglycemic drugs.  
 Patients use insulin pens during the time of the study. 
3.3 Period of the study 
  
The pilot study data were collected during August 2016 and the final data were 
collected between November 2016 and April 2017. 
 
3.4 Ethical approval  
 
Ethical approval for the study was obtained from the Ministry of Health (Appendix 
E). Each patient was provided with explanation about the study. Patients were informed 
that they can refuse to participate, can discontinue their participation at any point and they 
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could refuse to answer any question. Verbal consent was obtained from each patient before 
the beginning of questionnaire completion.  
According to the MOH recordings the average number of patients use insulin and 
visits MOH primary health clinics is 275 in Bethlehem while in Hebron the average is 
1750; distributed as 553 patients in South Hebron clinics, 332 patients in North Hebron 
clinics and 866 in Middle Hebron. The sample used was 311 patients distributed as 114 
patients in Bethlehem and 196 patients in Hebron, distributed as 70 subjects in South 
Hebron, 20 subjects in North Hebron and 107 in Middle Hebron. The population size in 
Bethlehem and Hebron is large so we collected a convenient sample of 12% of the 
population.  
3.5 Experts Review 
 
The SF-36 is a validated questionnaire that was used exactly as provided by the 
vendor. Other parts of the questionnaire like the socio-demographic and WTP domains, 
were forwarded to three clinical research experts for review. The reviewers were asked to 
provide feedback. All reviewers approved the questionnaire after it was modified 
according to their suggestions.   
3.6 Pilot study 
 
We performed a pilot study of the WTP domain in order to test if it is appropriate 
and clear for the patients. It was also important to test reliability and validity of this part of 
the questionnaire. 
3.7 Data collection 
 
All eligible patients were approached as they came in for routine follow-ups during 
the data collection period in the primary health clinics. Every consecutive patient who 
arrived at the clinics was approached in the waiting area. Patients who met the study 
inclusion criteria were asked if they were willing to participate in the study by completing 
the questionnaire while they were waiting to see the doctor. Verbal consent was obtained 
from each patient prior to completing the questionnaire. The interview with participants 
needed from 15 to 20 minutes.  
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3.8 Data Analysis 
 
The questionnaires were filled and the data for QoL part were introduced in the 
QualityMetric Health Outcomes™ Scoring Software 4.0. The results were in a scale of 0 to 
100. These results from the software were introduced into the SPSS program. 
SPSS program was used for analysis of the current study findings and to correlate 
the mean differences in the different components of the questionnaire; PF, RP, RE, BP, 
GH, VT, SF, MH, MCS and PCS with the independent variables of; age group, sex, level 
of education, marital status, employment status, monthly household income, type of 
diabetes, duration of diabetes, insulin regimen and the duration of insulin use. 
A one-way Analysis of Variance (ANOVA) was used to compare differences 
between subgroups of independent categorical variables. Post-hoc analyses (Scheffé’s Post 
hoc Test) was then conducted to test for differences between the groups to determine if the 
overall ANOVA was statistically significant. For interpretation of the results, P <0.05 was 
considered to be statistically significant. Confidence intervals were calculated at the 95% 
level of confidence. 
       Multiple regression analysis was used to test which variables significantly predicted 
PCS and MCS.  
 
3.9 Null hypothesis 
 
H1: There is no statistical difference between males and females regarding QOL.   
H2: There is no significant relationship between age and QOL. 
H3: There is a significant relationship between QOL and residency in Bethlehem or 
Hebron. 
H4: There is no significant relationship between social relationship and QOL. 
H5: There is no significant relationship between educational level and QOL. 
H6: There is no significant relationship between job and QOL. 
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H7: There is no significant relationship between place of living and QOL. 
H8: There is no significant relationship between the number family members  
and QOL. 
H9: There is no significant relationship between monthly income and QOL. 
H10: There is no significant relationship between the duration of diabetes  
disease and QOL. 
H11: There is no significant relationship between the type of diabetes and  
QOL. 
H12: There is no significant relationship between poor glycemic control  
(HbA1c > 7%) and QOL. 
H13: There is no significant relationship between the number of insulin types  
the patient use and QOL. 
H14: There is no significant relationship between the duration of insulin use  
and QOL. 
H15: There is no significant relationship between the number of times the  
patient administer insulin and QOL. 
H16: There is no significant relationship between diabetes complications and  
QOL. 
H17: There is no significant relationship between the patient's choice to use  
insulin pens and QOL. 
H18: There is no significant relationship between the amount of money the  
patient is willing to pay for insulin pens and QOL. 
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Chapter 4: Results 
 
4.1 WTP part pilot study 
 
 The coefficient alpha (or Cronbach’s alpha) was used to assess the internal 
consistency of the WTP part.  The alpha value was 0.83 which indicated that the 
instrument is reliable. 
As shown in Table 1 all the correlation coefficients indicated that this part of the 
questionnaire has a good internal consistency. 
 
Table 1: summary of the correlation coefficient and significance of the WTP part. 
Reasons to choose pens over 
syringes 
Correlation 
Coefficient 
P value 
Easier to use .455 .029 
Easier to inject .795 .000 
More accurate in measuring the 
dose. 
 
.491 .019 
Need less time for the injection .777 .000 
Causes less pain .557 .008 
More lifestyle and social life 
flexibility 
.714 .000 
Reading the dose is easier .702 .001 
 
4.2 Description of the socio-demographic data of the participants 
 
Table 2 displays the socio-demographic characteristics of participants. The results 
revealed that 48% of participants were males and 52% females, the majority of them 84.9 
% were married while 15.1 % had no partner. The mean age was 50.6±Sd 15.7 years, age 
distribution shows that 25.3% of subjects were between the age of (17-40) years, 38.9% 
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between (41-59) years, and 35.7% were above 60 years, around 75 % of participants are 
older than 40 years and that is due to the nature of late onset of DM. Patients living in 
towns formed 37.3 % of the participants, 61.4 % lived in cities and 1.3% lived in camps. 
15.1% of the sample had a full time job and 5.5% had a part time job while the majority 
79.1% was unemployed. About 35% had no formal school education and are assumed to be 
illiterate, 51.4% had only primary school or secondary education, about 5% had diploma 
and 8.4% had a vocational education.  The majority of the subjects 81.7% had an income 
of less than 3000, 13.2% had 3000-4000 while only 5% had an income of more than 4000 
Israeli Shekels per month. 
 
Table 2: distribution of the participants by socio-demographic characteristics 
 
Variable  Frequency Percent 
Age 
17-40 78 25.3% 
41-59 120 38.9% 
60 and more 110 35.7% 
Gender 
Female 162 52.1% 
Male 149 47.9% 
Marital status 
married 264 84.9% 
widow 21 6.8% 
single 25 8.0% 
divorced 1 0.3% 
Education level 
No schooling        110 35.% 
Elementary school 
and secondary 
160 
51.% 
diploma 15 4.8% 
Professional  26 8.4% 
Employment status 
Full time job 47 15.% 
Part time job 17 5.5% 
Not work 246 79.% 
other 1 0.3% 
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Place of living 
town 116 37.% 
city 191 61.% 
camp 4 1.3% 
Monthly income 
Less than 3000 254 81.% 
3001-4000 41 13.% 
More than 4000 16 5.1% 
 
4.3 Results of the health profile: 
 
Results of the health profile are shown in Table 3. 
Most subjects 86.5% had type 2 and 13.5% had type 1 diabetes. 28% of participants 
said they did not receive counseling to increase disease awareness about the disease while 
71.7% said they did and mostly from the health care providers in the MOH clinics. 92% of 
subjects reported that they received practical information from health care providers on 
how to use the injections while 8% reported they didn’t.  Patients were asked if they make 
sure that the syringe had no air bubbles before they inject themselves, 91% of them said 
they did and 9% said they didn’t. 
The majority 64% of subjects use Mixtard
®
, a pre-mixed neutral suspension of 
human insulin, to control their blood sugar, most patients 71.7% used one type of insulin 
while 19.3% of patients use two types. Almost 50% of the subjects reported that they had 
hypoglycemia in the past four weeks. When patients were asked about their insulin 
regimen; 67.5% of participants reported they used insulin two times daily, 22.8% three 
times and 9.6% once daily.  
The mean level of HbA1c was 9% with a standard deviation of 2. The majority of 
patients (97%) (254 patients) had HbA1c level of 7 and higher while only 3% (8 patients) 
had HbA1c level of less than 7. 
Table 3: health profile information of participants 
Independent variable  frequency Percent 
Diabetes type 
 
Type 2 269 86.5% 
Type 1 42 13.5% 
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Did the patient received 
Awareness about the disease 
No 88 28.3% 
Yes 223 71.7% 
Did any healthcare provider 
explained to the patient how 
to use insulin injection 
 
yes 286 92% 
No 25 8% 
Do the patient make sure 
that the injection have no 
air bubbles 
yes 283 91% 
No 28 9% 
HbA1c level 
< 7.0% 8 3% 
≥ 7% 254 97% 
Type of insulin 
NPH
®
 84 27% 
Actrapid
®
 60 19% 
Mixtard
®
 199 64% 
Number of insulin types 
used by patients 
1 223 71.7% 
2 60 19.3% 
Did you have hypoglycemia 
in the past four weeks 
Yes 169 54% 
no 142 45% 
Insulin regimen 
Once 30 9.6% 
twice 210 67.5% 
Three times 71 22.8% 
 
4.4 Diabetes duration, insulin use duration and health Complications Associated with 
Diabetes: 
 
Results are shown in Table 4 
Participants had been diagnosed with diabetes from less than a year to 59 years 
with a mean of 14.9 years (standard deviation = 13.6), most patients had been diagnosed 
with diabetes for more than 11 years. The average duration of using insulin in our sample 
was 6.6 years and the majority of patients had been using insulin for less than five years. 
21.6% of patients reported they had one complication, 23.8% reported two complication 
and 31.4% reported from 3 to 7 complications. 
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A multiple-response item asked participants to report the most common diabetes-
related complications they experienced; the most frequent complication was visual 
disorders (58%), followed by neurological disorders (42%), heart disease (31%), stroke 
(22%), renal complications (16%) and foot ulcers (14%). The least common complication 
was gangrene (Table 4). On the other hand 23% of subjects reported they had no 
complications of diabetes. 
Table 4: Results of Diabetes duration, insulin use duration and health 
Complications Associated with Diabetes 
Variable  frequency Percent 
Diabetes duration 
0-5 52 16.7% 
6-10 73 23.5% 
>10 185 59.6% 
Diabetes complications 
 
 
Eye problems 180 58% 
Kidney disease 51 16% 
Nerve damage or 
neuropathy 
132 42% 
Heart Disease (e.g. 
angina, heart attack) 
97 31% 
Stroke 67 22% 
Foot ulcers 42 14% 
Gangrene and/or 
amputation 
4 1% 
None of the above 70 23% 
Number of complications 
1 67 21.6% 
2 74 23.8% 
3 54 17.4% 
4 28 9% 
>5 16 5% 
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4.5 WTP results: 
 
As shown in Table 5, 58.2 % reported that if both choices pens and syringes were 
available they will choose pens and 41.8% will choose syringes. 41.8% of participants 
didn’t answer the question if they are willing to pay more for the pens, 35.4% reported they 
will and about 23% reported that they will not pay more. 11% reported they were willing 
to pay extra 10 NIS in order to get the pens and 7% were willing to pay 20 NIS, 4.5% and 
3.9% were willing to pay 40 and 50NIS respectively and 4.5% were willing to pay 100NIS. 
The most common two reasons reported by participants for choosing pens were that 
they are easier to use and inject than syringes. On the other hand the majority of patients 
92% reported that they chose vials because they are used to them. Patients reported that 
they chose syringes because they are easy to use, they believe that they were more able to 
control their blood sugar 77% and less cost 72%. 
Table 5: the results of WTP part. 
Variable  frequency percent 
Choice pen/syringe 
 
pens 181 58.2% 
Vial/syringe 130 41.8% 
Paying extra for the pens 
 
yes 110 35.4% 
no 71 22.8% 
No answer 130 41.8% 
Willingness to pay 
 
5 2 0.6% 
10 35 11.2% 
15 2 0.6% 
20 22 7.1% 
30 3 1% 
40 14 4.5% 
50 12 3.9% 
60 2 0.6% 
70 1 0.3% 
100 14 4.5% 
120 1 0.3% 
200 3 1% 
31 
 
 
What was important to you 
when you chose pens? 
 
 
Easier to use 
 
166 
 
92% 
Easier to inject 158 87% 
More accurate in 
measuring the 
dose. 
 
120 66% 
Need less time for the 
injection 
126 70% 
Causes less pain 117 65% 
More lifestyle and 
social life flexibility 
149 82% 
Reading the dose is 
easier 
143 79% 
What was important to you 
when you chose 
vial/syringe. 
 
used to use it 120 92% 
Less cost 93 72% 
Hard to learn to use 
pens 
44 34% 
Easy to use vials 105 81% 
Easy to inject by 
syringe 
95 73% 
Feel more confident 
about the dose 
accuracy 
83 64% 
Less painful 44 34% 
Syringes don’t 
interfere with daily 
activities 
90 69% 
Easy to read the dose 100 77% 
Believe to be more 
able to control blood 
sugar 
100 77% 
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4.6 QOL domains mean scores 
 
 
Table 6: Mean, Standard deviation and percentages of participants whose scores 
were above or below the general population norm 
Domains Mean SD
1
 
Above the 
general 
population 
norms (%) 
Below the 
general 
population 
norms (%) 
Physical Component Summary 
(PCS) 
41.42 11.67 17 63 
Physical Functioning (PF) 58.92 31.2 19 56 
Role Physical (RP) 44.25 36.72 17 68 
Bodily Pain (BP) 49.03 32.64 21 60 
General Health (GH) 48.3 22.0 12 58 
Mental Component Summary 
(MCS) 
41.32 12.19 15 59 
Vitality (VT) 40.73 27.01 18 59 
Social Functioning (SF) 65.61 36.23 43 45 
Role Emotional (RE) 58.91 34.59 30 60 
Mental Health (MH) 54.25 24.33 16 62
2
 
  
Table 6 showed the mean scores of the quality of life domains. The domain with 
the highest score was social functioning (M = 65.6, SD = 36.2), followed physical 
functioning (M= 58.91, SD= 31.2) and role emotional (M = 58.91, SD = 34.58). The lowest 
was vitality (M = 40.7, SD = 27). The mean scores for physical component summary (M = 
41.4, SD = 31.2) was lower than mental component summary (M = 54.25, SD = 24.3). 
According to the norm based scoring which were applied a linear T-score 
transformation (M = 50, SD = 10) (
                                                           
1 SD: Standard deviation  
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Appendix G), the quality of life among patients who had scores of quality of life 
below than the general population norm in physical component score (PCS), physical 
functioning (PF), role physical (RP), body pain (BP), general health (GH), mental 
component score (MCS), vitality (VT), social functioning (SF), role emotional (RE), and 
mental health (MH) domains with the percentages of 63, 56, 68, 60, 58, 59, 59, 45, 60, and 
62, respectively. More importantly, the percentage of patients that had scores above the 
general population norms appears relatively low for all domains (ranging from 12% to 
30%). The domain with the highest percentage above the general population norms was 
social functioning with 43%.   
 
4.7 Gender and age 
 
As shown in Table 7 and Appendix F there was no significant relationship between 
gender and QoL domains except for body pain in which men had a higher score than 
women.  
There was no significant relationship between age and QoL domains (Appendix E).  
4.8 Residency 
 
T- test (Appendix F) was performed to evaluate the effect of residency on QoL, the 
mean score of all domains was higher for patients in Bethlehem relative to Hebron. A 
significant relationship was observed with the domains of role limitation due to physical 
health (RF) (p 0.001), general health (GH) (p 0.012), vitality (VT) (p 0.037), mental health 
(MH) (p 0.027), physical component summary (PCS) (p 0.012) and mental component 
summary (MCS) (p 0.037).  
4.9 Marital status 
 
Single patients had higher scores in all domains compared to married and widow. 
ANOVA test (Appendix F) showed that the relationship was significant in physical 
functioning, role limitation due to physical functioning, body pain, social functioning, role 
limitation due to emotional problems and physical component summary. LSD test showed 
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(Appendix F) that single participants had higher mean scores than married and widow in 
those six domains. 
4.10 Level of education 
 
Participants' level of education was found to be significantly associated with all 
QoL domains (Table 7) (Appendix F). LSD test (Appendix F) was performed to test for the 
differences in QoL domains by participants' level of education; it was found that 
participants who were illiterate had lower mean scores in all domains than those who had 
primary or secondary education, diploma and university level of education. 
4.11 Occupation 
 
ANOVA and LSD tests (Appendix F) showed that in PCS, RE, SF, VT, GH, BP, 
RF and PF aspects of QoL there was a significant positive relationship between working 
and QoL. In particular, participants who have a full time or a part time job had higher 
mean scores in those QoL domains. 
4.12 Place of living 
 
There was no significant relationship between the place of living; village, city or 
camp and QoL domains (Appendix F).  
4.13 Number of family members 
 
In order to examine the relationship between the number of family members and 
QoL we did Pearson test (Appendix F) and there was no significant relationship.  
4.14 Monthly income 
 
ANOVA test was performed to examine the relationship between income and QoL 
(Appendix F), monthly income had a significant relationship with the domains of physical 
functioning, role limitation due to physical functioning, social functioning and role 
limitation due to emotional problems (Table 7). LSD test (Appendix F) showed that 
participants with higher income had a higher mean QoL scores.  
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4.15 Diabetes duration 
 
The results of ANOVA test (Appendix F) showed significant relationship between 
PF, RP, BP and PCS QOL domains and diabetes duration (Table 8). The mean scores for 
all QOL domains except role emotional, mental health and mental component summary 
were lower in patients who had been diagnosed with diabetes for longer duration. The 
worst values were reached after 10 years as shown in Appendix E. 
4.16 Duration of using insulin use 
 
ANOVA test (Appendix F) showed that there was no significant relationship 
between the duration of using insulin and QoL. 
4.17 Diabetes type 
 
The mean scores for all QoL domains were higher for type 2 diabetes as shown in 
Appendix E. The relationship between QoL and diabetes type was significant in PF, RP, 
BP, GH, VT, SF and PCS according to the ANOVA test (Appendix F).  
4.18 HbA1c level 
 
T- test (Appendix F) was performed to examine the effect of HbA1c level on QoL. 
As seen in table 8 there was no significant relationship between QoL and HbA1c levels. 
 
4.19 Number of insulin types used by the patient 
 
T-Test (Appendix F) was performed to examine the effect of number of insulin 
types used on QoL domains. The majority of patients (78.7%) had been using one type of 
insulin, Mixtard
®
, and 21.2% had been using two types of insulin to control their blood 
sugar. As shown in table 8 there was a significant relationship between PF, PR and PCS 
QoL domains and the number of insulin types, the mean scores of QoL domains  for the 
patients use two types was higher than those use one type.  
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4.20 Insulin regimen 
 
Patients use insulin once daily had a higher score in GH domain compared to the 
other regimens (Appendix F). In other domains the difference was not significant (Table 
8). 
4.21 Patients' choice to use insulin pens  
 
The relationship between patients' choice to use insulin pens or syringes was 
assessed by t-test (appendix F). The results showed a significant relation with the physical 
functioning and physical component summary domains. The mean score for the PF domain 
among participants that chose pens was 62.6 compared to 53.77 for those who chose 
syringes. The same trend applies to the PCS domain; the mean score for patients chose 
pens was 42.56 and 39.8 for patients chose syringes.  
4.22 Diabetes complications 
 
According to the ANOVA test (appendix F), in all QoL domains there was a 
significant relationship between the number of diabetes complications the patient's had and 
QoL. The mean scores for all QoL domains were higher for patients with lower number of 
complications.  
Table 7: summary of the associations between independent variables of the socio-
demographic characteristics of participants with QOL domains. 
       
                 Eight Aspects 
Demographic 
Characteristics 
 
PF 
 
RF 
 
BP 
 
GH 
 
VT 
 
SF 
 
RE 
 
MH 
 
PCS 
 
MCS 
Age NS NS NS NS NS NS NS NS NS NS 
Gender NS NS 0.000 NS NS NS NS NS NS NS 
Place of  residency 
(Bethlehem/Hebron) 
NS 0.001 NS 0.012 0.037 NS NS 0.027 0.012 0.037 
Marital status 0.000 0.000 0.001 NS NS 0.029 0.043 NS 0.000 NS 
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NS: Non significant 
Table 8: summary of the associations between independent variables of the health 
profile of participants with QoL domains 
 
 
NS: Non significant 
 
 
Education level 0.000 0.000 0.001 0.008 0.000 0.002 0.009 0.000 0.000 0.001 
Employment status 0.000 0.002 0.001 0.003 0.006 0.001 0.008 NS 0.000 NS 
Place of living NS NS NS NS NS NS NS NS NS NS 
Number of family  
members 
NS NS NS NS NS NS NS NS NS NS 
Monthly income 0.018 0.039 NS NS NS 0.004 0.006 NS NS NS 
       
           Eight Aspects 
 
Health profile 
PF RF BP GH VT SF RE MH PCS MCS 
Diabetes duration 0.000 0.014 0.038 NS NS NS NS NS 0.000 NS 
Duration of using 
insulin 
NS NS NS NS NS NS NS NS NS NS 
Diabetes type 
0.000 0.000 0.000 0.000 0.000 0.001 NS NS 0.000 NS 
HbA1c level 
NS NS NS NS NS NS NS NS NS NS 
Number of  insulin 
types 
0.001 0.022 NS NS NS NS NS NS 0.009 NS 
Insulin regimen 
NS NS NS 0.025 NS NS NS NS NS NS 
Patient's choice 
pens/syringes 
0.013 NS NS NS NS NS NS NS 0.045 NS 
Diabetes 
complications 
0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000 
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4.23 Multiple regression analysis 
 
Multiple regression analysis was used to test which variables significantly predicted 
PCS and MCS.  
The results of the regression (table 9) indicated the type of diabetes, duration of 
diabetes, level of education and employment were significant predictors of PCS. These 
four predictors explained 26.9% of the variance in PCS; type of diabetes caused 14.2% of 
the variance followed by duration of diabetes (5.8%), level of education (4.7%) and 
employment (2.2%).   
Table 9: Multiple regression analysis of PCS. 
 
Model Summary 
Model R R Square 
Adjusted R 
Square 
Std. Error of 
the Estimate 
Change Statistics 
R Square 
Change 
F Change df1 df2 
Sig. F 
Change 
dimension0  
1 .377a .142 .140 10.827 .142 50.773 1 306 .000 
2 .447b .200 .195 10.474 .058 21.972 1 305 .000 
3 .497c .247 .240 10.178 .047 19.000 1 304 .000 
4 .519d .269 .260 10.044 .022 9.181 1 303 .003 
a. Predictors: (Constant), type of diabetes 
b. Predictors: (Constant), type of diabetes, duration of diabetes 
c. Predictors: (Constant), type of diabetes , duration of diabetes , level of education 
d. Predictors: (Constant), type of diabetes   , duration of diabetes  , level of education, employment 
Dependent Variable: PCS 
 
 
On the other hand MCS was significantly predicted by level of education as seen in 
table 10. 
Table 10: Multiple regression analysis of MCS. 
 
Model Summary 
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Model R R Square 
Adjusted R 
Square 
Std. Error of 
the Estimate 
Change Statistics 
R 
Squar
e 
Chan
ge 
F 
Change 
df1 df2 Sig. F 
Change 
 1 .196
a
 .038 .035 11.972 .038 12.215 1 306 .001 
a. Predictors: (Constant), level of education 
 
Dependent Variable: MCS 
Dependent variable: MCS 
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Chapter 5: Discussion 
 
5.1 Health-related quality of life among patients with T1DM and T2DM Taking 
Insulin 
 
In this study, the domain that had the highest score was social functioning (M = 
65.6, SD = 36.2) and the lowest was vitality (M = 40.7, SD = 27). The mean scores for 
physical component summary (M = 41.42, SD = 11.671) and for mental component 
summary (M = 41.32, SD = 12.18). In all dimensions and the two components summary 
scores, except social functioning, most of participants had scores of quality of life lower 
than the general population norm. When compared to a recent study assessed QoL in 
general population in the West Bank that used SF36 in university students (ASI, 2015) this 
study scores as seen in Table  were lower in all domains except RE.  
Table 11: QoL mean scores of general population in the West Bank (ASI, 2015) 
 
Domains Mean SD3 
Physical Component 
Summary (PCS) 
72.2 17 
Physical Functioning (PF) 77.4 24.5 
Role Physical (RP) 68.2 34.7 
Bodily Pain (BP) 77.2 20.7 
General Health (GH) 63.2 15.6 
Mental Component 
Summary (MCS) 
55.3 20.2 
Vitality (VT) 53.6 18.5 
Social Functioning (SF) 66.6 23.4 
Role Emotional (RE) 50.2 41.7 
Mental Health (MH) 56.1 20.3 
 
 
These results agrees with a previous study that used SF36 to assess QoL of type 2 
diabetics in North West Bank (Showli, 2013). Previous study in Gaza (Eljedi et al., 2006) 
used WHOQOL-BREF questionnaire and found that diabetic patients scored lower than 
                                                           
3
 SD: Standard deviation 
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controls in physical and psychological domains and a smaller difference was identified in 
social relationships.  
These result are also consistent with other studies examined QoL in diabetic 
patients and found that diabetes mellitus affected health-related quality of life of the 
participants  (Glasgow et al., 1997; Porojan, Poantă, & Dumitraşcu, 2012). 
When compared to a study in New Delhi (Gautam, Sharma, Agarwal, Bhatnagar, & 
Trehan, 2009) that used SF36 to assess QoL of diabetic patients all domains except general 
health were lower in our study.  
Compared to a recent study in Saudi Arabia, the scores of our study were lower in 
all domains except social functioning compared to the Saudi patients' scores that used 
insulin alone and lower in all domains compared to patients used insulin and oral 
hypoglycemic drugs together (Al Hayek et al., 2014). 
 
5.2 Factors related to QoL 
5.2.1 Glycemic control 
 
We found no significant relationship between glucose control (HbA1c levels) and 
QoL. Most studies found no relationship between glucose control and QoL (Ahroni, 
Boyko, Davignon, & Pecoraro, 1994; Cong et al., 2012; Rubin & Peyrot, 1999; 
Weinberger et al., 1994). On the other hand some studies suggested that a relationship does 
exist (Alkarmi, 2013). 
A study that used both disease specific questionnaire (Diabetes Quality of Life 
Scale) and the generic SF-36 found a significant relationship between DQOL and HbA1c 
while no significant relationship between HbA1c and any domain of SF36 (Trief, Grant, 
Elbert, & Weinstock, 1998). These results could be due to the fact that SF36 is not as 
sensitive as disease specific questionnaires to therapy related effects on QoL. 
5.2.2 Complications 
 
77% of participants reported having complications. This study showed that 
complications had a very clear significant effect on all QoL domains. It is found that 
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patients who did not develop any complications had better means of the QoL domains than 
those who had only one complication, and as the number of complications increase the 
QoL mean scores decrease. Similar results were observed in a study conducted in Gaza 
camps (Eljedi et al., 2006) and in a study conducted with type 1 diabetic patients in North 
West Bank (Alkarmi, 2013).  
There are also many other studies that showed a negative impact of complications 
on QoL (Ahroni et al., 1994; Graff & McClanahan, 1998; E. S. Huang et al., 2007). 
5.2.3 Number of insulin injections per day 
 
Our data showed that the only aspect affected by the number of insulin injections 
was general health; the mean score of once daily was better than that of twice and three 
injections while in the other aspects there was no significant difference. Some studies 
showed that the number of insulin injections negatively affected QoL (Alkarmi, 2013; E. S. 
Huang et al., 2007; G.-H. Huang, Palta, Allen, LeCaire, & D’Alessio, 2004). In contrast, 
other studies found no significant relationship between daily injections and QoL (Eiser et 
al., 1992). 
5.2.4 Number of insulin types used by patients 
 
In our study, patients who used two types of insulin achieved higher PF, PR and 
PCS QoL domains mean scores than those used one type. Some studies reported a better 
quality of life with a more intensified regimens (Wagner, Müller–Godeffroy, Von 
Sengbusch, Häger, & Thyen, 2005). This better QoL could be related to the more flexible 
diet and a better glycemic control with intensive insulin treatment. 
5.2.5 Diabetes type 
 
This study found that the mean scores of PF, RP, BP, GH, VT, SF and PCS QoL 
domains were higher for type 2 than type 1 diabetes. These results are consistent with other 
studies that found that Type 2 diabetic patients had a significantly better quality of life than 
type 1 patients on the physical functioning and social functioning QoL domains (Jacobson, 
De Groot, & Samson, 1994). On the other hand another study found that depression and 
anxiety does not differ significantly between diabetes types (Peyrot & Rubin, 1997). The 
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differences between the two types could be due to the differences in age and treatment 
regimens (Rubin & Peyrot, 1999).  
5.2.6 Duration of diabetes 
 
The longer duration of diabetes had a negative effect on QoL, our study showed 
that PF, RP, BP and PCS QoL domains mean scores were significantly lower for patients 
with longer duration of disease, these results agreed with a previous study in Gaza that 
assessed the QoL of type 2 diabetes patients and showed that after 10 years of diabetes 
diagnosis, QoL started to decrease significantly (Eljedi et al., 2006). Many other studies 
reported that with longer duration of diabetes QoL decreased (Glasgow et al., 1997; G.-H. 
Huang et al., 2004). 
On the other hand some studies found no significant relationship between QoL and 
diabetes duration (Ahroni et al., 1994; Wredling et al., 1995). 
5.2.7 Duration of using insulin 
 
Our results showed no significant relationship between the duration of using insulin 
and QoL. These results agrees with other studies that confirmed that QoL does not change 
with the follow up of patients after initiation of insulin (De Sonnaville et al., 1998). 
Another study showed that with time the QoL for patients that use insulin decreased 
(Davis, Clifford, & Davis, 2001). 
5.2.8 Income 
 
Patients with higher income scored higher in PF, RF, SF and RE. In all QoL 
domains patients with a monthly income more than ₪3000 scored better than patients with 
income less than ₪3000 this was consistent with a study that found that diabetic patients 
who had more than ₪1800 monthly income had better QoL than who have no regular 
income (Eljedi et al., 2006). Many studies reported that less income was associated with 
lower QoL in diabetic patients (Glasgow et al., 1997).  These results are consistent with 
another study used SF-36 to assess the effect of socio-economic status on QoL and 
indicated that low income correlated with lower QoL (Pappa, Kontodimopoulos, 
Papadopoulos, & Niakas, 2009).  
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5.2.9 Gender 
 
As shown in appendix E there was no significant relationship between gender and 
QoL except in BP domain, this result is consistent with other studies that assessed the QoL 
of diabetic patients in Gaza (Eljedi et al., 2006) and in northern districts in the West Bank 
(Alkarmi, 2013). On the other hand, it is the opposite of a previous study conducted with 
type 2 diabetic patients in Northern Palestine that confirmed that females had a lower QoL 
compared to males (Showli, 2013). Many studies in other populations showed there was no 
significant relationship between gender and QoL in diabetic patients while others showed a 
lower QoL in women (G.-H. Huang et al., 2004; Jacobson et al., 1994; Peyrot & Rubin, 
1997; Wredling et al., 1995). 
5.2.10 Age 
 
This study indicated no significant relationship between QoL and age. Other studies 
showed that older age was associated with higher risk of being more depressed (Peyrot & 
Rubin, 1997), another study used SF20 questionnaire indicated that lower age was 
associated with better physical functioning (Glasgow et al., 1997)  and the same result was 
shown using DQOL (Diabetes quality of life questionnaire) (Davis et al., 2001). This study 
disagreed with results obtained from studies in Palestine; in Gaza (Eljedi et al., 2006) and 
in North West Bank (Showli, 2013), which showed that age affected social and physical 
domains of QoL significantly. 
Other studies agreed with this study indicating no effect of age on any domain of 
QoL using SF-36 questionnaire on patients of type 1 and 2 diabetes (Jacobson et al., 1994). 
These results also agreed with a Swedish study with diabetic patients (Wredling et al., 
1995).  
5.2.11 Education 
 
In this study it was found that better education was linked to better QoL in all 
domains, which agreed with another study assessed QoL of diabetic patients using SF-20 
(Glasgow et al., 1997), other studies also found that being less educated was associated 
with higher risk of being anxious and depressed (Peyrot & Rubin, 1997). SF-36 was used 
in assessing QoL in type 1 diabetics (Alkarmi, 2013) and found that higher education was 
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related to only higher scores in emotional well being domain, it also was used in assessing 
type 2 diabetic patients QoL (Showli, 2013), which concluded that higher education 
affected social and physical domains of QoL.  
These results could be due to the possibility that educated people have better self-
esteem, better opportunity for employment, higher income and better social life. 
Our results disagreed with other studies that found no effect of education on QoL 
(Jacobson et al., 1994). 
5.2.12 Marital status 
 
This study showed that single patients had higher scores in all domains compared 
to married and widow. There was a significant relationship in PF, RF, BP, SF, RE and 
PCS. These results consisted with another study that assessed the effect of insulin therapy 
on QoL and indicated that being married inversely affected QoL using DQOL instrument 
(Davis et al., 2001). 
On the other hand, other studies indicated that married patients scored better in the 
well being scale and treatment satisfaction than widowed and divorced (Bott, Mühlhauser, 
Overmann, & Berger, 1998; Jacobson et al., 1994). 
5.2.13 Employment 
 
Our study as shown in appendix E showed that being employed was associated 
with better QoL in all domains, this result agrees with the findings of Eljedi et.al (Eljedi et 
al., 2006) in Gaza and with other studies (Trief et al., 1998). 
5.2.14 Residency 
 
Diabetic patients living in Bethlehem had better QoL in RF, GH, VT, MH, PCS and 
MCS. These results disagrees with the results of a study examined the relationship between 
type 2 diabetes QoL and residency (Showli, 2013). 
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5.2.15 Place of living  
 
There was no significant difference in QoL between patients lives in village, city or 
camps in this study. These results agreed with a previous study in Iran that concluded no 
significance different between patients lived in rural or urban areas (Nejhad, Vardanjani, 
Abolhasani, Hadipour, & Sheikhzadeh, 2013). 
5.3 Hypoglycemia 
 
54% reported hypoglycemia in the past month, consisted with other studies 
reported almost the same percentage (Weinberger et al., 1994). 
5.4 Willingness to pay 
 
58% of patients preferred insulin pens over syringes to administer insulin, the 
results of this study are consistent with previous studies that assessed the preference of 
patients for insulin pens and more than 70% of patients preferred to use pens (Graff & 
McClanahan, 1998; Korytkowski et al., 2003) (Stockl et al., 2007). 35% of patients 
reported they will pay more to get insulin pens but mostly from ₪10-20. Patients were not 
willing to make a substantial out-of-pocket payment might be because diabetic patients 
registered in the MOH clinics are used to paying only a co-payment out of pocket for the 
prescription each month.  
The major reason for choosing pens was that they found pens easier to use and 
inject than syringes. Those who preferred syringes stated their comfort with the insulin 
syringes as the major reason. 
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Chapter 6: Conclusion and recommendations 
  
In the present study, we interviewed 311 patients, who administer insulin by 
vial/syringe, including type 1 and 2 diabetic patients. The interviews took place in the 
MOH clinics in Bethlehem and Hebron.  Type 2 diabetes was present in 86.5% of subjects. 
Seventy four percent of the respondents were above 40 years old, 52% were females, the 
majority (85%) was living with their partners at the time of the study, 35.4% of patients 
were illiterate. 79% of them were unemployed, most participants 60% were living in cities, 
the majority 81.7% had an income of less than ₪3000 per month. The mean duration of 
diabetes among respondents in the present study was 14.9 ± 13.6 years. 77% of patients 
had complications and the most common complication observed in our diabetic patients 
was eye problems (58%).  
The majority of participants had lower QoL than the general population norms and 
the scores of all domains except the physical and social functioning were below 50, which 
indicated a low QoL.  
QoL of Diabetic patients using insulin was influenced by residency, marital status, 
level of education, employment, monthly income, diabetes duration, diabetes type, diabetes 
complications and insulin regimen. On the other hand it was not affected by gender, age, 
duration of using insulin and glycemic control.  
Most patients (58%) preferred to use pens if it was available as a choice for insulin 
administration, and the majority of them were not willing to pay more than what they pay 
now for their insulin prescription monthly.  
The number of diabetic patients in Palestine is increasing. One of the main 
objectives of DM treatment program is to promote the QoL in diabetic patients, our results 
indicated a low QoL. A close look at the health care system is needed in order to try to 
improve QoL by possible introduction of insulin pens as a choice for diabetic patients 
using insulin. The introduction of insulin pens will make insulin self-administration easier 
and will decrease the discomfort of injection, which will increase compliance and as a 
result diabetes complications in the future.  
48 
 
References  
 
Abu-Rmeileh, Niveen ME, Ghandour, Rula, Mataria, Awad, Awawda, Sameera, Jabr, 
Samer, & O'Flaherty, Martin. (2017). Time to act on diabetes mellitus prevention in 
the West Bank, oPt: Current and future direct cost of diabetes and its 
complications. Obesity Medicine, 6, 18-22.  
Ahroni, Jessie H, Boyko, Edward J, Davignon, Denise R, & Pecoraro, Roger E. (1994). 
The health and functional status of veterans with diabetes. Diabetes Care, 17(4), 
318-321.  
Al Hayek, Ayman A, Robert, Asirvatham A, Al Saeed, Abdulghani, Alzaid, Aus A, & Al 
Sabaan, Fahad S. (2014). Factors associated with health-related quality of life 
among Saudi patients with type 2 diabetes mellitus: a cross-sectional survey. 
Diabetes & metabolism journal, 38(3), 220-229.  
Alkarmi, R. (2013). Quality of life and determinants among Diabetes Mellitus type 1 
patients attending the MoH PHC centers in the northern districts of West Bank. 
(master), Al-Quds University, Pelestine.    
Anderson, Robert M, Fitzgerald, James T, Wisdom, Kimberlydawn, Davis, Wayne K, & 
Hiss, Roland G. (1997). A comparison of global versus disease-specific quality-of-
life measures in patients with NIDDM. Diabetes care, 20(3), 299-305.  
Asamoah, Ernest. (2008). Insulin pen—the ―iPod‖ for insulin delivery (why pen wins over 
syringe). Journal of diabetes science and technology, 2(2), 292-296.  
ASI, Y. (2015). IS CONFLICT A FACTOR IN A POPULATION’S QUALITY OF LIFE? A 
COMPARATIVE STUDY OF UNIVERSITY STUDENTS IN THE PALESTINIAN 
TERRITORIES AND JORDAN. (Doctor of Philosophy), University of Central 
Florida, Florida.    
Association, American Diabetes. (2005). Diagnosis and classification of diabetes mellitus. 
Diabetes care, 28, S37.  
Association, American Diabetes. (2012). Standards of medical care in diabetes—2012. 
Diabetes care, 35(Supplement 1), S11-S63.  
Bala, Mohan V, Mauskopf, Josephine A, & Wood, Lisa L. (1999). Willingness to pay as a 
measure of health benefits. Pharmacoeconomics, 15(1), 9-18.  
Bohannon, Nancy JV. (1999). Insulin delivery using pen devices: simple-to-use tools may 
help young and old alike. Postgraduate Medicine, 106(5), 57-68.  
49 
 
Bott, UWE, Mühlhauser, Ingrid, Overmann, Hubert, & Berger, Michael. (1998). 
Validation of a diabetes-specific quality-of-life scale for patients with type 1 
diabetes. Diabetes care, 21(5), 757-769.  
Cheen, Hua Heng McVin, Lim, Seng Han, Huang, Ming Chien, Bee, Yong Mong, & Wee, 
Hwee Lin. (2014). Adherence to premixed insulin in a prefilled pen compared with 
a vial/syringe in people with diabetes in Singapore. Clinical therapeutics, 36(7), 
1043-1053.  
Cong, Ji‐Yan, Zhao, Yue, Xu, Qun‐Yan, Zhong, Chun‐De, & Xing, Qiu‐Ling. (2012). 
Health‐related quality of life among Tianjin Chinese patients with type 2 diabetes: 
A cross‐sectional survey. Nursing & health sciences, 14(4), 528-534.  
Control, Diabetes, & Group, Complications Trial Research. (1993). The effect of intensive 
treatment of diabetes on the development and progression of long-term 
complications in insulin-dependent diabetes mellitus. N Engl j Med, 329(14), 977-
986.  
Davis, Timothy ME, Clifford, Rhonda M, & Davis, Wendy A. (2001). Effect of insulin 
therapy on quality of life in type 2 diabetes mellitus: the Fremantle Diabetes Study. 
Diabetes research and clinical practice, 52(1), 63-71.  
De Sonnaville, Jeroen JJ, Snoek, Frank J, Colly, Louisa P, Devillé, Walter, Wijkel, Dirk, & 
Heine, Robert J. (1998). Well-being and symptoms in relation to insulin therapy in 
type 2 diabetes. Diabetes Care, 21(6), 919-924.  
Donaldson, Cam, Jones, Andrew M, Mapp, Tracy J, & Olson, Jan Abel. (1998). Limited 
dependent variables in willingness to pay studies: applications in health care. 
Applied Economics, 30(5), 667-677.  
Eiser, Christine. (2004). Use of quality of life measures in clinical trials. Ambulatory 
Pediatrics, 4(4), 395-399.  
Eiser, Christine, Flynn, M, Green, E, Havermans, T, Kirby, R, Sandeman, D, & Tooke, JE. 
(1992). Quality of life in young adults with type 1 diabetes in relation to 
demographic and disease variables. Diabetic Medicine, 9(4), 375-378.  
Eljedi, Ashraf, Mikolajczyk, Rafael T, Kraemer, Alexander, & Laaser, Ulrich. (2006). 
Health-related quality of life in diabetic patients and controls without diabetes in 
refugee camps in the Gaza strip: a cross-sectional study. BMC Public Health, 6(1), 
1.  
50 
 
Funnell, Martha M. (2008). Quality of life and insulin therapy in type 2 diabetes mellitus. 
Insulin, 3(1), 31-36.  
Gautam, Yogesh, Sharma, AK, Agarwal, AK, Bhatnagar, MK, & Trehan, Roochika 
Ranjan. (2009). A cross-sectional study of QOL of diabetic patients at tertiary care 
hospitals in Delhi. Indian journal of community medicine: official publication of 
Indian Association of Preventive & Social Medicine, 34(4), 346.  
Glasgow, Russell E, Ruggiero, Laurie, Eakin, Elizabeth G, Dryfoos, Janet, & Chobanian, 
Lisa. (1997). Quality of life and associated characteristics in a large national sample 
of adults with diabetes. Diabetes care, 20(4), 562-567.  
Graff, Marilyn R, & McClanahan, Mark A. (1998). Assessment by patients with diabetes 
mellitus of two insulin pen delivery systems versus a vial and syringe. Clinical 
therapeutics, 20(3), 486-496.  
. Health Report. (2016).  Palestine: Palestinian Health Information Center  
Hörnquist, Jan Olof, Wikby, Anders, Andersson, Per-Olof, & Dufva, Ann-Mari. (1990). 
Insulin-pen treatment, quality of life and metabolic control: retrospective intra-
group evaluations. Diabetes research and clinical practice, 10(3), 221-230.  
Huang, Elbert S, Brown, Sydney ES, Ewigman, Bernard G, Foley, Edward C, & Meltzer, 
David O. (2007). Patient perceptions of quality of life with diabetes-related 
complications and treatments. Diabetes care, 30(10), 2478-2483.  
Huang, Guan-Hua, Palta, Mari, Allen, Catherine, LeCaire, Tamara, & D’Alessio, Donn. 
(2004). Self-rated health among young people with type 1 diabetes in relation to 
risk factors in a longitudinal study. American journal of epidemiology, 159(4), 364-
372.  
Husseini, A. (2000). Prevalence of diabetes mellitus and impaired glucose tolerance in a 
rural Palestinian population.  
Husseini, A, Abu-Rmeileh, NME, & Mikki, N. (2009). Cardiovascular disease, diabetes 
mellitus, and cancer in the occupied Palestinian territory.(vol 373, pg 1041, 2009). 
Lancet, 373(9677), 1764-1764.  
Imseeh, S. (2013). Type 2 Diabetes Mellitus Management and Glycemic Control: Evidence 
from Ramallah Governorate Clinics – Palestine. (Master), Birzeit University.    
Jacobson, Alan M, De Groot, Mary, & Samson, Jacqueline A. (1994). The evaluation of 
two measures of quality of life in patients with type I and type II diabetes. Diabetes 
care, 17(4), 267-274.  
51 
 
Jendle, J, Torffvit, Ole, Ridderstråle, Martin, Lammert, M, Ericsson, Å, & Bøgelund, M. 
(2010). Willingness to pay for health improvements associated with anti-diabetes 
treatments for people with type 2 diabetes. Current medical research and opinion, 
26(4), 917-923.  
Kinge, H, Aubert, RE, & Herman, WH. (1998). Global burden of Diabetes 1995-2025. 
Diabetes care, 21(9), 1414-1431.  
Korytkowski, Mary, Bell, David, Jacobsen, Carol, Suwannasari, Rudee, & Team, 
FlexPen® Study. (2003). A multicenter, randomized, open-label, comparative, two-
period crossover trial of preference, efficacy, and safety profiles of a prefilled, 
disposable pen and conventional vial/syringe for insulin injection in patients with 
type 1 or 2 diabetes mellitus. Clinical therapeutics, 25(11), 2836-2848.  
Levin, Kate Ann. (2006). Study design III: Cross-sectional studies. Evidence-based 
dentistry, 7(1), 24-25.  
Lloyd, Andrew, Nafees, Beenish, Barnett, Anthony H, Heller, Simon, Ploug, Uffe J, 
Lammert, Morten, & Bøgelund, Mette. (2011). Willingness to pay for 
improvements in chronic long-acting insulin therapy in individuals with type 1 or 
type 2 diabetes mellitus. Clinical therapeutics, 33(9), 1258-1267.  
Mann, CJ. (2003). Observational research methods. Research design II: cohort, cross 
sectional, and case-control studies. Emergency medicine journal, 20(1), 54-60.  
Molife, Cliff, Lee, Lauren J, Shi, Lizheng, Sawhney, Monika, & Lenox, Sheila M. (2009). 
Assessment of patient-reported outcomes of insulin pen devices versus 
conventional vial and syringe. Diabetes technology & therapeutics, 11(8), 529-538.  
Nejhad, Zahra Hosseini, Vardanjani, Hossein Molavi, Abolhasani, Farid, Hadipour, 
Maryam, & Sheikhzadeh, Khodadad. (2013). Relative effect of socio-economic 
status on the health-related quality of life in type 2 diabetic patients in Iran. 
Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 7(4), 187-190.  
Pappa, Evelina, Kontodimopoulos, Nick, Papadopoulos, Angelos A, & Niakas, Dimitris. 
(2009). Assessing the socio-economic and demographic impact on health-related 
quality of life: evidence from Greece. International journal of public health, 54(4), 
241-249.  
Pawaskar, Manjiri D, Camacho, Fabian T, Anderson, Roger T, Cobden, David, Joshi, 
Ashish V, & Balkrishnan, Rajesh. (2007). Health care costs and medication 
adherence associated with initiation of insulin pen therapy in Medicaid-enrolled 
52 
 
patients with type 2 diabetes: a retrospective database analysis. Clinical 
therapeutics, 29(6), 1294-1305.  
Peyrot, Mark, & Rubin, Richard R. (1997). Levels and risks of depression and anxiety 
symptomatology among diabetic adults. Diabetes care, 20(4), 585-590.  
Peyrot, Mark, Rubin, Richard R, Lauritzen, Torsten, Skovlund, Soren E, Snoek, Frank J, 
Matthews, David R, . . . Kleinebreil, Line. (2005). Resistance to insulin therapy 
among patients and providers results of the cross-national Diabetes Attitudes, 
Wishes, and Needs (DAWN) study. Diabetes care, 28(11), 2673-2679.  
Polonsky, William H, & Jackson, Richard A. (2004). What's so tough about taking insulin? 
Addressing the problem of psychological insulin resistance in type 2 diabetes. 
Clinical diabetes, 22(3), 147-150.  
Porojan, M, Poantă, LAURA, & Dumitraşcu, DL. (2012). Assessing health related quality 
of life in diabetic patients. Romanian journal of internal medicine= Revue 
roumaine de medecine interne, 50(1), 27-31.  
Pousinho, Sarah, Morgado, Manuel, Falcão, Amílcar, & Alves, Gilberto. (2016). 
Pharmacist interventions in the management of type 2 diabetes mellitus: a 
systematic review of randomized controlled trials. Journal of managed care & 
specialty pharmacy, 22(5), 493-515.  
Rubin, Richard R, & Peyrot, Mark. (1999). Quality of life and diabetes. 
Diabetes/metabolism research and reviews, 15(3), 205-218.  
Sarah, Wild, Gojka, Roglic, Anders, Green, Richard, Sicree, & Hilary, King. (2004). 
Global prevalence of diabetes. Diabetes care, 27(5), 1047-1053.  
Shaw, Jonathan E, Sicree, Richard A, & Zimmet, Paul Z. (2010). Global estimates of the 
prevalence of diabetes for 2010 and 2030. Diabetes research and clinical practice, 
87(1), 4-14.  
Showli, O.;  Sarsure, A.;   Naalwa, A.;  Rsheed, A.;  Hawari, A. (2013). Quality of life for 
patient with type II Diabetes in North of West Bank. (Master), An-Najah National 
University.    
Speight, J, Reaney, MD, & Barnard, KD. (2009). Not all roads lead to Rome—a review of 
quality of life measurement in adults with diabetes. Diabetic Medicine, 26(4), 315-
327.  
Stockl, Karen, Ory, Caron, Vanderplas, Ann, Nicklasson, Lars, Lyness, William, Cobden, 
David, & Chang, Eunice. (2007). An evaluation of patient preference for an 
53 
 
alternative insulin delivery system compared to standard vial and syringe. Current 
medical research and opinion, 23(1), 133-146.  
Sweileh, Waleed M, Sa’ed, H Zyoud, Nab’a, Rawan J Abu, Deleq, Mohammed I, Enaia, 
Mohammed I, Sana’a, M Nassar, & Al-Jabi, Samah W. (2014). Influence of 
patients’ disease knowledge and beliefs about medicines on medication adherence: 
findings from a cross-sectional survey among patients with type 2 diabetes mellitus 
in Palestine. BMC Public Health, 14(1), 94.  
Theofilou, Paraskevi. (2013). Quality of life: definition and measurement. Europe’s 
Journal of Psychology, 9(1), 150-162.  
Trief, Paula M, Grant, William, Elbert, Katja, & Weinstock, Ruth S. (1998). Family 
environment, glycemic control, and the psychosocial adaptation of adults with 
diabetes. Diabetes care, 21(2), 241-245.  
Wagner, Verena M, Müller–Godeffroy, Esther, Von Sengbusch, Simone, Häger, Stefan, & 
Thyen, Ute. (2005). Age, metabolic control and type of insulin regime influences 
health-related quality of life in children and adolescents with type 1 diabetes 
mellitus. European journal of pediatrics, 164(8), 491-496.  
Ware Jr, John E. (2000). SF-36 health survey update. Spine, 25(24), 3130-3139.  
Ware Jr, John E, & Sherbourne, Cathy Donald. (1992). The MOS 36-item short-form 
health survey (SF-36): I. Conceptual framework and item selection. Medical care, 
473-483.  
Weinberger, Morris, Kirkman, M Sue, Samsa, Gregory P, Cowper, Patricia A, Shortliffe, E 
Anne, Simel, David L, & Feussner, John R. (1994). The relationship between 
glycemic control and health-related quality of life in patients with non-insulin-
dependent diabetes mellitus. Medical care, 1173-1181.  
Woodcock, Alison J, Julious, Steven A, Kinmonth, Ann Louise, & Campbell, Michael J. 
(2001). Problems with the performance of the SF-36 among people with type 2 
diabetes in general practice. Quality of Life Research, 10(8), 661-670.  
Wredling, R, Stålhammar, J, Adamson, U, Berne, C, Larsson, Y, & Östman, J. (1995). 
Well-being and treatment satisfaction in adults with diabetes: a Swedish 
population-based study. Quality of Life research, 4(6), 515-522.  
Wubben, Deborah P, & Vivian, Eva M. (2008). Effects of pharmacist outpatient 
interventions on adults with diabetes mellitus: a systematic review. 
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 
28(4), 421-436.    
 45
 
 secidneppA
 
 A xidneppA
 
 :ٍؼيٍ٘بد شخظٞخ ػِ اىَشٝغ
  اىدْظ                   
 روش                          o
 أٔضٝ o
  ................... اىؼَش  
 :اىحبىخ الاخزَبػٞخ اىشإْخ
 أسًِ o  ِزضٚط o
 ِطٍك o  أػضة o
 اىَغز٘ٙ اىزؼيَٜٞ
 غ١ش ِزؼٍُ o
 صبٔٛٞ فألً o
 ) دثٍَٛ اٌؼٕب٠خ ثبلأؽفبي أٚ ِٛظف رمِٕٟضً ( دثٍَٛ  o
 ) حلاّق أٚ ؽجبخ ( ِٕٟٙ أٚ ِزذسة  o
 )ثىبٌٛس٠ٛط ( شٙبدح عبِؼ١خ  o
 دساعبد ػٍ١ب o
 ............................غ١ش رٌه حذد  o
 ؟ اى٘ظٞفٜ ى٘ػؼل ٗطف أفؼو ٕ٘ ٍب
 )وبًِ ثذٚاَ ( رؼًّ o
 رؼًّ ثذٚاَ عضئٟ o
 لا رؼًّ o
 ............................غ١ش رٌه حذد  o
 
 ٍنبُ اىغنِ
 لش٠خ o
 اٌّذ٠ٕخ o
 ِخ١ُ o
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 ............................ ػذد افشاد الاعشح
 
 :اىَظبدس خَٞغ ٍِ ثبىشٞنو اىشٖشٛ دخو الأعشح ٝظف اىزبىٞخ اىَؼذلاد ٍِ أٛ
 0003ألً ِٓ لً ِٓ  o
  1003 - 0004 o
 0004 اوضش ِٓ  o
 
 :اىحبىخ اىظحٞخ
 ؟ٍْز مٌ ػبً رٌ رشخٞظل ثبلاطبثخ ثبىغنشٛ
 عٕخ............... 
 ؟ ٍْٔ رؼبّٜ اىزٛ اىغنشٛ ّ٘ع ٕ٘ ٍب
  الإٔغٌٛ١ٓ إٌٝ ٠حزبط اٌزٞ اٌضبٟٔ إٌٛع o
  الأٚي إٌٛع o
 
 اىغنشٛ؟ٍشع  ثخظ٘ص ر٘ػٞخ ػيٚ حظيذ ٕو
 لا o
   ...........................  ِزٝ؟ .............................................. ؟ أ٠ٓ ؛ ٔؼُ o
 
 ٍؼيٍ٘بد ػِ مٞفٞخ اعزخذاً حقِ الاّغ٘ىِٞ؟ٕو حظيذ ػيٚ 
 ٔؼُ                        لا
 .ٕو رزأمذ ٍِ ػذً ٗخ٘د فقبػبد اىٖ٘اء داخو اىغشّح قجو حقْٖب رحذ اىديذ
 ٔؼُ                                         لا
 
 .................................. .فٜ اىذً c1AbHٍغز٘ٙ اه 
 
  لاّغ٘ىِٞ اىزٛ رغزخذٍٔ؟ٍب أّ٘اع ا
     HPN o
 65
 
    dipartcA o
     dratxiM o
 ٍْز ٍزٚ ٗاّذ رغزخذً الاّغ٘ىِٞ؟
 شٙش/ عٕخ .................. 
 :خلاه اخش شٖش ٕو حذس ٍؼل ٕج٘ؽ فٜ اىغنش فٜ اىذً ٗاٛ ٍِ ٕزٓ الاػشاع 
 لا o ٔؼُ o
 
 اٌغٛع o
 
 خفمبْ o
 اٌمٍت ثشى ًٍ عش٠غ     
 
 رؼشق o
             ػذَ ٚػٛػ  o
 اٌشؤ٠ب ٚاٌضغٍٍخ        
 دٚخخ o اٌظذاع o
 رضبؤة ِغزّش o
 غض١بْ o
 اٌؼظج١خ ٚعشػخ  o
 اٌغؼت           
 اٌشؼٛس ثبٌجشد o اٌزؼت ٚإٌؼبط o
 فشؽ الاوً o طؼٛثخ فٟ اٌىلاَ o
 
 :مٌ ٍشح رحقِ الاّغ٘ىِٞ   فٜ اىًٞ٘
 ِشح ٚاحذح o
 ِشر١ٓ o
 صلاس ِشاد o
 
 ىغنشٛ؟ثب ذ الاطبثخثؼ ػْذك اىزبىٞخ اىَؼبػفبد ٍِ أٛ رشخٞض ٗرٌ حظو ٕو
 
  ).اٌغٍٛغِٛب اٌضسق أٚ اٌىٕزبساد اٌؼذعخ أٚإػزبَ اٌشجى١خ اػزلاي ِضً ( اٌؼ١ٕ١ٓ فٟ ِشبوً o
 75
 
  اٌىٍٝ عاأِش o
  اٌؼظجٟ الإػزلاي أٚ الاػظبة رٍف o
  )اٌمٍج١خ إٌٛثخ أٚ اٌظذس٠خ اٌزثحخ ِضً )اٌمٍت أِشاع o
  اٌغٍطخ o
 اٌمذِ١ٓ فٟ رمشػ o
  اٌغبل١ٓ أحذ ثزش أٚ اٌغشغش٠ٕب o
 .أػلاٖ اٌّزوٛسح الأػشاع ِٓ أٞ أػبٟٔ لا o
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 B xidneppA
 
 طحزل ٗسفبٕٞزل
 
 
عزغبػذ ٕزٓ اىَؼيٍ٘بد فٜ رزجغ شؼ٘سك ٗمٞف  .ٝغأه ٕزا الاعزجٞبُ ػِ ٗخٖخ ّظشك ح٘ه طحزل
 !عزجٞبُشنشا لإمَبىل ٕزا الا  .قبدسا ػيٚ اىقٞبً ثْشبؽبرل الاػزٞبدٝخ ثشنو خٞذ ذمْ
 .ٝظف ثأفؼو شنو إخبثزل فٜ اىَشثغ اىزٛ اىشخبء ٗػغ إشبسح  فٜ مو ٗاحذ ٍِ الأعئيخ اىزبىٞخ،
 ثشنو ػبً، ر٘د أُ رق٘ه أُ طحزل... .1
 ػؼ١فخ ِؼزذٌخ ع١ّذح ع١ّذح عذا ِّزبصح
     
     5      4      3      2      1 
 
 
 
 ثشنو ػبً؟ اٌُٟ طحزل مٞف رقٞ   ثبىَقبسّخ ٍغ اىغْخ اىَبػٞخ، .2
أفؼً ثىض١ش ا٢ْ 
ثبٌّمبسٔخ ِغ اٌؼبَ 
 اٌّبػٟ
أفؼً ٔٛػب ِب 
ا٢ْ ثبٌّمبسٔخ ِغ 
 اٌؼبَ اٌّبػٟ
رمش٠جب ٔفظ اٌؼبَ 
 اٌّبػٟ
أعٛأ ٔٛػب ِب ا٢ْ 
ثبٌّمبسٔخ ِغ اٌؼبَ 
 اٌّبػٟ
أعٛا ثىض١ش ا٢ْ 
ثبٌّمبسٔخ ِغ اٌؼبَ 
 اٌّبػٟ
     
     5      4       3      2      1 
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 ٕو رقٞذك. ّشبؽبد ٍِ اىََنِ أُ رقً٘ ثٖب خلاه ًٝ٘ ػبدٛ هالأعئيخ اىزبىٞخ رذٗس ح٘ .3
 أٛ ٍذٙ؟ ٚإرا مبّذ مزىل، فئى  طحزل اُٟ فٜ اىْشبؽبد اىزبىٞخ؟
 
 ذٟٔ ٔؼُ، رم١ّ   
 وض١شا
 ذٟٔ رم١ّ  ٔؼُ،
 لٍ١لا
ذٟٔ رم١ّ  لا، لا
 ػٍٝ الإؽلاق
    
 ، ِضً اٌشوغ، سفغ أش١بء صم١ٍخ، إٌشبؽبد اٌمٛ٠خ ا. 
 3 ............... 2  ................ 1  ............................................ اٌّشبسوخ فٟ س٠بػخ شبلخ
 دفغ ِىٕغخ  ،رحش٠ه ؽبٌٚخ ًِض ،إٌشبؽبد ِؼزذٌخ اٌشذح ة. 
 3 ............... 2  ................ 1  .............................. اٌغجبحخ أٚ سوٛة اٌذساعخ ،وٙشثبئ١خ
 3 ............... 2  ................ 1  ................................................... سفغ أٚ حًّ ِٛاد اٌجمبٌخ .ط 
 3 ............... 2  ................ 1  ............................................. ؽٛاثك ػذحطؼٛد اٌذسط  .د 
 3 ............... 2  ................ 1  ............................................. ٚاحذطؼٛد اٌذسط ؽبثك  .ٖ 
 3 ............... 2  ................ 1  ..................... الأحٕبء، اٌّشوٛع، أٚ ؽأؽأح اٌشأط ٚاٌىزف١ٓ .ٚ 
 3 ............... 2  ................ 1  ....................................... ٚاحذ أوضش ِٓ و١ٍِٛزش ٌّشٟا .ص 
 3 ............... 2  ................ 1  ......................................... ػذح ِئبد ِٓ الأِزبساٌّشٟ  .ػ 
 3 ............... 2  ................ 1  ......................................................... ِئخ ِزشاٌّشٟ  .ؽ 
 3 ............... 2  ................ 1  .........................................الاعزحّبَ أٚ اسرذاء اٌّلاثظ .ٞ 
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، مٌ ٍِ اى٘قذ ٗاخٖذ أٝب ٍِ اىَشبمو اىزبىٞخ فٜ ػَيل أٗ الأعبثٞغ الأسثؼخ اىَبػٞخخلاه  .4
 ؟ّزٞدخ ىظحزل اىدغذٝخخ الاػزٞبدٝخ الأخشٙ ّشبؽبرل اىٍٞ٘ٞ
ٚلا فٟ أٞ  لٍ١ً ِٓ اٌٛلذ ثؼغ اٌٛلذ ِؼظُ اٌٛلذ و ًّ اٌٛلذ 
 ٚلذ
 
  اٌزٞ لؼ١زٗ فٟ وّ١خ اٌٛلذأخفبع فٟ  ا. 
 5   ............4   ..............3   ............ 2   .............1   ....................... اٌؼًّ أٚ إٌشبؽبد الأخشٜ
 5   ............4   ..............3   ............ 2   .............1   ................................ ِّب رش٠ذ أٔغضد ألً ة. 
 اٌؼًّ أٚ إٌشبؽبد ٔٛع ذا/ح فٟوٕذ ِم١ّ  .ط 
 5   ............4   ..............3   ............ 2   .............1   ................................................الأخشٜ
 فٟ أداء ػٍّه أٚ إٌشبؽبد طؼٛثخٚاعٙذ  د. 
 5   ............4   ..............3   ............ 2   .............1   ....... ِٕه عٙذا إػبف١ب). دالأخشٜ (ِضلا، أخز
 
ٞبٍل ٗاخٖذ أٝب ٍِ اىظؼ٘ثبد اىزبىٞخ أثْبء ق مٌ ٍِ اى٘قذ، أعبثٞغ الأسثؼخ اىَبػٞخخلاه  .5
(ٍثو الإحغبط  ٍشبمو ٍزؼيقخ ثبىؼبؽفخثؼَيل أٗ ثأّشطزل اىؼبدٝخ اىٍٞ٘ٞخ الأخشٙ ثغجت أٛ 
 ثبلإمزئبة أٗ اىقيق)؟
ٚلا فٟ أٞ  لٍ١ً ِٓ اٌٛلذ ثؼغ اٌٛلذ ِؼظُ اٌٛلذ و ًّ اٌٛلذ 
 ٚلذ
 
 اٌزٞ لؼ١زٗ فٟ  وّ١خ اٌٛلذأخفبع فٟ  ا. 
 5   ............4   ..............3   ............ 2   .............1   ....................... اٌؼًّ أٚ إٌشبؽبد الأخشٜ
 5   ............4   ..............3   ............ 2   .............1   ....................... ِّب وٕذ رشغتأٔغضد ألً  ة. 
 ثحزس ألً لّذ ثؼًّ أٚ ٔشبؽبد أخشٜ  ط. 
 5   ............4   ..............3   ............ 2   .............1   ............................................ ِٓ اٌّؼزبد
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إىٚ أٛ ٍذٙ رذخيذ ٍشبميل اىدغذٝخ أٗ اىؼبؽفٞخ فٜ ، الأعبثٞغ الأسثؼخ اىَبػٞخخلاه  .6
 غ اىؼبئيخ، الأطذقبء، اىدٞشاُ، أٗ اىَدَ٘ػبد؟ّشبؽبرل الاخزَبػٞخ الاػزٞبدٝخ ٍ
 حثشذ وض١شا ثشىً ِؼزذي لٍ١لا لا ػٍٝ الإؽلاق
     
     5      4      3      2      1 
 
 
 ؟بثٞغ الأسثؼخ اىَبػٞخالأعػبّٞذ خلاه  اىدغذٛمٌ ٍِ الأىٌ  .7
 شذ٠ذ عذا شذ٠ذ ِزٛعؾ خف١ف خف١ف عذا لا شٟء
      
     6      5      4       3       2       1 
 
 
ثؼَيل الاػزٞبدٛ (ثَب فٞٔ اىؼَو  الأىٌ، إىٚ أٛ ٍذٙ رذخو الأعبثٞغ الأسثؼخ اىَبػٞخخلاه  .8
 خبسج اىجٞذ أٗ اىؼَو اىجٞزٜ)؟
 حثشذ وض١شا ثشىً ِؼزذي لٍ١لا لا ػٍٝ الإؽلاق
     
     5      4       3       2       1 
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 . الأعبثٞغ الأسثؼخ اىَبػٞخٕزٓ الأعئيخ رغزفغش ػِ شؼ٘سك ٗمٞف عبسد الأٍ٘س ٍؼل خلاه  .9
مٌ ٍِ اى٘قذ خلاه  .عؤاه، اىشخبء إػطبء اىد٘اة الأقشة إىٚ اىطشٝقخ اىزٜ شؼشد ثٖبىنو 
 ...الأعبثٞغ الأسثؼخ اىَبػٞخ
 
 
 
فٜ ّشبؽبرل  اىؼبؽفٞخ ٍشبميل ل اىدغذٝ خ أٗطح  ز، مٌ ٍِ اى٘قذ رذخيذ الأعبثٞغ الأسثؼخ اىَبػٞخخلاه  .11
 الاخزَبػٞخ (ٍثو اىقٞبً ثضٝبساد ىلأطذقبء، الأقبسة، اىخ.)؟
 ٚلا فٟ أٞ ٚلذ لٍ١ً ِٓ اٌٛلذ ثؼغ اٌٛلذ ِؼظُ اٌٛلذ و ًّ اٌٛلذ
     
     5      4       3       2       1 
 
 
 
 ٚلا فٟ أٞ لٍ١ً ِٓ اٌٛلذ ثؼغ اٌٛلذ ِؼظُ اٌٛلذ و ًّ اٌٛلذ 
 ٚلذ
 
 5  ............ 4  .............. 3  ............. 2  .............. 1  .................................. ؟ شؼشد ثبٌح١ٛ٠خ  ا. 
 5  ............ 4  .............. 3  ............. 2  .............. 1  ........................ شؼشد ثأٔه ػظج ّٟ /ح عذاً؟ ة. 
 شؼشد ثأٔه ِحجؾ/ح عذا ثح١ش أٗ ي ط. 
 5  ............ 4  .............. 3  ............. 2  .............. 1  .............................. ا شٟء ٠ّىٕٗ إعؼبدن؟
 5  ............ 4  .............. 3  ............. 2  .............. 1  ........................ شؼشد ثبٌٙذٚء ٚاٌطّأٔ١ٕخ؟ د. 
 5  ............ 4  .............. 3  ............. 2  .............. 1  ............................ ج١شح؟وبٔذ ٌذ٠ه ؽبلخ و .ٖ 
 5  ............ 4  .............. 3  ............. 2  .............. 1  .................. ؟شؼشد ثأٔه حض٠ٓ/ح ِٚىزئت/ح .ٚ 
 5  ............ 4  .............. 3  ............. 2  .............. 1  ............................... /ح؟شؼشد ثأٔه ِٕٙه .ص 
 5  ............ 4  .............. 3  ............. 2  .............. 1  .................................... شؼشد ثبٌغؼبدح؟ .ػ 
 5  ............ 4  .............. 3  ............. 2  .............. 1  ...................................... شؼشد ثبٌزؼت؟ ؽ. 
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 ٍِ اىؼجبساد اٟرٞخ ثبىْغجخ ىل؟ موٍب ٍذٙ طحخ أٗ خطأ  .11
ثشىً ِطٍك  
 طح١حخ
ػٍٝ الأغٍت 
 طح١حخ
ػٍٝ الأغٍت  لا أػشف
 خبؽئخ
 ثشىً ِطٍك
 خبؽئخ
      
 ٠جذٚ أّٟٔ أوضش عٌٙٛخ فٟ اٌزؼّشع ٌٍّشع ا. 
 5  .......... 4  ........... 3  ........... 2  .......... 1  ................................ ِٓ أشخبص آخش٠ٓ.
 ثٕفظ لذس اٌغلاِخ اٌزٟ ٠زّزّغ ثٙب  /حأٔب عٍ١ُ .ة 
 5  .......... 4  ........... 3  ........... 2  .......... 1  .................................... أٞ شخض أػشفٗ
 5  .......... 4  ........... 3  ........... 2  .......... 1  ..................... أرٛلغ أْ رضداد طحزٟ عٛءا. .ط 
 5  .......... 4  ........... 3  ........... 2  .......... 1  ...................................... طّحزٟ ِّزبصح. .د 
 
 
 
 
 
 
 
 شنشا لإمَبىل ٕزٓ الأعئيخ!
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 C xidneppA
 
 الاعزؼذاد ىذفغ ٍجيغ ٍِ اىَبه ٍقبثو اىحظ٘ه ػيٚ اقلاً الاّغ٘ىِٞ ثذلا ٍِ الاثش
ثٛعٛد اٌمٍُ ٚاٌششػ ٌٍّش٠غ ػٕٗ ٚػٓ و١ف١خ (ٔفزشع رٛفش اللاَ الأغٌٛ١ٓ وبداح ٌحمٓ الأغٌٛ١ٓ 
 )اعزخذاِٗ
 :ثبلإثشاعزخذاَ الاللاَ ِمبسٔخ 
 خ ٍِ قجيل حبىٞبالاثش اىؼبدٝخ اىَغزخذٍ اقلاً الاّغ٘ىِٞ
 .اٌٝ ػجٛح أغٌٛ١ٓ ثبلإػبفخ٠زٛعت ػٍ١ه حًّ اٌمٍُ 
 
 ).اٌغشٔظ(٠غت ػٍ١ه حًّ صعبعخ الأغٌٛ١ٓ ٚاٌّحمٓ 
  
ٌزحذ٠ذ اٌغشػخ اٌّطٍٛثخ رحزبط اٌٝ اخز١بس اٌغشػخ ِٓ صس 
 . اٌغشػخ اٌّٛعٛد ػٍٝ اٌمٍُ
ادخً ,  عحت ٘ٛاء اٌٝ داخً اٌحمٕخ ثّمذاس اٌغشػخ ٠غت 
  ٝ داخً ػٍجخ الأغٌٛ١ٓ ػجش اٌغطبءالاثشح اٌ
  اعحت الأغٌٛ١ٓ ِٓ اٌؼٍجخ ثّمذاس اٌغشػخ, اٌّطبؽٟ
ػٕذ ٚعٛد . لاحع الأغٌٛ١ٓ داخً اٌحمٕخ ,  اٌّطٍٛثخ
 ٠غت اصاٌزٙب ٚاٌزأوذ ِٓ صٚاٌٙب.٘ٛائ١خ  فمبػبد
ٌحمٓ الأغٌٛ١ٓ رغشص الإثشح رحذ عٍذن ٚرٕمش ِٓ صُ ػٍٝ 
 .ٔغٌٛ١ٓصس فٟ ؽشف اٌمٍُ ٌزٛط١ً الأ
أغشص ثغشػخ وً الإثشح . أِغه اٌحمٕخ ِضً لٍُ اٌشطبص
  .دسعخ 00فٟ ؽ١خ عٍذن ٚفك صاٚ٠خ لذس٘ب 
أفٍذ اٌغٍذ ٚاحمٓ الأٔغٌٛ١ٓ ِٓ خلاي دفغ اٌّىجظ ثشفك  
 .ٚثٛر١شح ِؼزذٌخ ِٚطّشدح
 .ِٓ الاللاَاعزخذاَ الاثش ٠حزبط ٚلذ اوجش  .ٚ٠حزبط ٚلذ الً ٌحمٓ الأغٌٛ١ٓ, ِٓ اٌغًٙ اعزخذاَ اٌمٍُ
 .حمٓ الاثش ٠غجت أٌُ اوجش .اعزخذاَ اٌمٍُ ٠غجت أٌُ ألً ػٕذ اٌحمٓ
 .أذ اطلا رغزخذَ اثش الأغٌٛ١ٓ ٚرؼشف و١ف١خ اعزخذاِٙب .رؼٍُ و١ف١خ اعزخذاَ اٌمٍُ ػٍ١ه
 
 :ٍب اىزٛ رخزبسٓ م٘عٞيخ ىحقِ الاّغ٘ىِٞ
 الاثش  o الاللاَ o
ىزٛ رذفؼٔ حبىٞب ٍقبثو الاثش ٗالاّغ٘ىِٞ ىيحظ٘ه ػيٚ قيٌ ٕو ػْذك اعزؼذاد ىذفغ ٍجيغ امجش ٍِ ا  
 الاّغ٘ىِٞ م٘عٞيخ ىيحقِ
 ٔؼُ o
     لا o
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اىزٛ رغزطٞغ دفؼٔ صٝبدح ػيٚ اىَجيغ اىزٛ رذفؼٔ  ثبىشٞنو اىَيغ مٌ , ػغ ثبػزجبسك دخيل اىشٖشٛ
 :ىحقِ الاّغ٘ىِٞ اخزٞبس اىقيٌ م٘عٞيخٍقبثو  حبىٞب
 
 ارا مبُ اخزٞبسك الاقلاً 
 :ىلاقلاًِب ٟ٘ اٌظفبد اٌّّٙخ اٌزٟ حذدد اخز١بسن 
 لا ّؼٌ اىظفخ
   عٌٙٛخ اٌزؼبًِ ِغ اٌمٍُ ِٓ ٔبح١خ عٌٙٛخ اٌحًّ ِمبسٔخ ثبلاثش
   عٌٙٛخ اٌحمٓ ِمبسٔخ ثبلاثش
   أصك اوضش ثبٕٟٔ احمٓ اٌغشػخ اٌّطٍٛثخ ثذلخ اوجش ِٓ الاثش
   اعزخذاَ اٌمٍُ ٠حزبط ٚلذ الً
   الاٌُ ػٕذ اٌحمٓ ٠ىْٛ الً
   ػذَ رأص١ش اٌمٍُ ػٍٝ ح١بره ٚٔشبؽبره اٌ١ِٛ١خ
   عٌٙٛخ لشاءح اٌغشػخ
 
  ارا مبُ اخزٞبسك الاثش
 :ىلاثش ٗاىغشّحِب ٟ٘ اٌظفبد اٌّّٙخ اٌزٟ حذدد اخز١بسن 
 لا ّؼٌ اىظفخ
   اػز١بدن ػٍٝ اعزخذاَ الاثش
   الالً ٌلاثشاٌزىٍفخ 
   طؼٛثخ رؼٍُ اعزخذاَ الاللاَ
   عٌٙٛخ اٌزؼبًِ ِغ الاثش
   عٌٙٛخ اٌحمٓ 
   أصك اوضش ثبٕٟٔ احمٓ اٌغشػخ اٌّطٍٛثخ ثذلخ اوجش ِٓ الاللاَ
   الاٌُ ػٕذ اٌحمٓ ٠ىْٛ الً
   ػذَ رأص١ش الاثش ػٍٝ ح١بره ٚٔشبؽبره اٌ١ِٛ١خ
 002 اوضش ِٓ o 051 o 001 o 06 o 04 o 02 o 01 o
 002 o 021 o 07 o 05 o 03 o 51 o
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   عٌٙٛخ لشاءح اٌغشػخ
   زحىُ ثّغزٜٛ اٌغىش فٟ اٌذَ اوضشاٌمذسح ػٍٝ اٌ
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Appendix F 
 
Results Appendix 
Gender 
The averages of QoL domains and T-test for the relationship between gender and QoL 
domains. 
QOL domains Gender N
4
 Mean   
Std. 
deviation 
T df
5
 Sig. (2- tailed) 
PF F 162 56.61 31.57 -1.310 309 .191 
M 149 61.24 30.73 
RP F 162 46.95 35.89 1.282 309 .201 
M 149 41.61 37.57 
BP F 161 42.43* 30.68 -3.805 308 .000 
M 149 56.23 33.18 
GH F 162 46.76 21.41 -1.330 309 .184 
M 149 50.07 22.53 
VT F 160 38.98 27.84 -1.211 307 .227 
M 149 42.70 25.99 
SF F 162 64.20 36.21 -.730 309 .466 
M 149 67.20 36.20 
RE F 162 56.40 34.27 -1.353 308 .177 
M 148 61.71 34.72 
MH F 160 52.75 24.37 -1.105 307 .270 
M 149 55.81 24.19 
PCS F 160 40.72 11.74 -1.117 307 .265 
M 149 42.20 11.56 
MCS F 160 40.52 11.86 -1.198 307 .232 
M 149 42.18 12.47 
 
Age 
The averages of QoL domains and ANOVA test for the effect of age on QoL domains 
 QOL Age N
6
 Mean Std. Deviation 
                                                           
4
 N: Number of subjects 
5
 Df: degree of freedom 
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domains 
PF    17-40 78 56.22 31.97 
41-59 120 62.21 30.97 
>60 more 110 57.23 31.18 
RP    17-40 78 45.19 35.91 
41-59 120 44.06 37.68 
>60 more 110 43.75 36.87 
BP  17-40 78 54.05 31.12 
41-59 120 49.78 33.35 
>60 more 109 44.92 32.84 
GH  17-40 78 49.97 23.38 
41-59 120 49.05 22.00 
>60 more 110 46.62 21.08 
VT    17-40 77 43.51 28.25 
41-59 119 41.75 27.64 
>60 more 110 37.78 25.57 
SF   17-40 78 61.38 37.21 
41-59 120 70.42 33.80 
>60 more 110 64.20 37.61 
RE    17-40 78 57.16 36.85 
41-59 119 57.14 34.23 
>60 more 110 61.33 33.32 
MH  17-40 77 54.68 27.04 
41-59 119 54.29 24.42 
>60 more 110 54.23 22.37 
PCS   17-40 77 42.08 11.87 
41-59 119 42.23 11.75 
>60 more 110 40.16 11.53 
MCS   17-40 77 41.01 13.18 
41-59 119 41.36 12.08 
>60 more 110 41.52 11.77 
 
 
ANOVA 
QOL domains 
Sum of Squares df Mean Square F Sig. 
PF    Between 
Groups 
2181.594 2 1090.797 1.113 .330 
Within Groups 298822.573 305 979.746   
Total 301004.167 307    
RP    Between 
Groups 
100.926 2 50.463 .037 .964 
Within Groups 416466.647 305 1365.464   
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Total 416567.573 307    
BP  Between 
Groups 
3874.559 2 1937.279 1.821 .164 
Within Groups 323388.418 304 1063.778   
Total 327262.977 306    
GH  Between 
Groups 
593.193 2 296.596 .611 .544 
Within Groups 148137.612 305 485.697   
Total 148730.805 307    
VT    Between 
Groups 
1672.597 2 836.298 1.141 .321 
Within Groups 222090.679 303 732.973   
Total 223763.276 305    
SF   Between 
Groups 
4359.047 2 2179.524 1.676 .189 
Within Groups 396748.907 305 1300.816   
Total 401107.955 307    
RE    Between 
Groups 
1231.622 2 615.811 .515 .598 
Within Groups 363826.421 304 1196.797   
Total 365058.043 306    
MH  Between 
Groups 
10.248 2 5.124 .009 .991 
Within Groups 180490.487 303 595.678   
Total 180500.735 305    
PCS   Between 
Groups 
285.213 2 142.606 1.042 .354 
Within Groups 41483.037 303 136.908   
Total 41768.250 305    
MCS   Between 
Groups 
12.015 2 6.008 .040 .961 
Within Groups 45524.008 303 150.244   
Total 45536.023 305    
 
 
Place of residency 
Averages and T-Test to evaluate the effect of residency on QOL. 
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QOL 
domain Residency N
7
 Mean 
Std. 
Deviation 
T df Sig. (2-tailed) 
PF Bethlehem 114 63.33 30.24 1.961 308 .051 
Hebron 196 56.15 31.60    
RP Bethlehem 114 53.73* 37.97 3.431 308 .001 
Hebron 196 39.13 35.02    
BP Bethlehem 113 53.04 32.27 1.659 307 .098 
Hebron 196 46.66 32.67    
GH Bethlehem 114 52.36* 23.00 2.532 308 .012 
Hebron 196 45.87 21.02    
VT Bethlehem 112 44.98* 28.53 2.099 306 .037 
Hebron 196 38.30 25.87    
SF Bethlehem 114 70.39 34.25 1.814 308 .071 
Hebron 196 62.69 37.05    
RE Bethlehem 114 63.16 37.28 1.700 307 .090 
Hebron 195 56.26 32.61    
MH Bethlehem 112 58.17* 24.14 2.215 306 .027 
Hebron 196 51.84 24.13    
PCS Bethlehem 112 43.63* 11.60 2.515 306 .012 
Hebron 196 40.18 11.56    
MCS Bethlehem 112 43.17* 12.48 2.100 306 .037 
Hebron 196 40.17 11.84    
*Significant at 0.05 level. 
                                                           
7
 N: Number of subjects 
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Marital status 
Averages and ANOVA test to assess the effect of marital status on QOL. 
QOL domain Marital status N Mean Std. Deviation 
PF 
MARRIED 
264 
56.82 30.55 
WIDOW 
21 
45.24 33.22 
SINGLE 
25 
90.80 12.05 
RP 
MARRIED 
264 
40.63 36.31 
WIDOW 
21 
49.11 35.15 
SINGLE 
25 
80.00 21.50 
BP 
MARRIED 
263 
48.33 32.52 
WIDOW 
21 
35.86 27.64 
SINGLE 
25 
69.04 29.78 
GH 
MARRIED 
264 
47.63 22.10 
WIDOW 
21 
48.43 16.94 
SINGLE 
25 
57.60 21.81 
VT 
MARRIED 
262 
39.89 27.00 
WIDOW 
21 
38.69 24.42 
SINGLE 
25 
52.50 27.48 
SF 
MARRIED 
264 
64.30 36.71 
WIDOW 
21 
61.90 36.12 
SINGLE 
25 
84.00 25.14 
RE 
MARRIED 
263 
57.27 35.14 
WIDOW 
21 
58.33 31.95 
SINGLE 
25 
75.33 25.40 
MH 
MARRIED 
262 
54.39 24.28 
WIDOW 
21 
58.81 21.09 
SINGLE 
25 
49.60 27.00 
PCS 
MARRIED 
262 
40.55 11.33 
WIDOW 
21 
37.64 10.88 
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SINGLE 
25 
54.09 7.65 
MCS 
MARRIED 
262 
41.21 12.42 
WIDOW 
21 
43.17 9.33 
SINGLE 
25 
41.09 12.14 
 
ANOVA 
 Sum of Squares Df Mean Square F Sig. 
PF    Between Groups 30498.712 2 15249.356 17.270 .000 
Within Groups 271078.963 307 882.993   
Total 301577.675 309    
RP    Between Groups 35911.272 2 17955.636 14.411 .000 
Within Groups 382522.321 307 1246.001   
Total 418433.594 309    
BP  Between Groups 13779.134 2 6889.567 6.720 .001 
Within Groups 313715.410 306 1025.214   
Total 327494.544 308    
GH  Between Groups 2270.684 2 1135.342 2.394 .093 
Within Groups 145606.764 307 474.289   
Total 147877.448 309    
VT    Between Groups 3734.577 2 1867.288 2.585 .077 
Within Groups 220276.178 305 722.217   
Total 224010.755 307    
SF   Between Groups 9192.524 2 4596.262 3.566 .029 
Within Groups 395706.669 307 1288.947   
Total 404899.194 309    
RE    Between Groups 7452.320 2 3726.160 3.173 .043 
Within Groups 359372.413 306 1174.420   
Total 366824.733 308    
MH  Between Groups 981.391 2 490.695 .831 .437 
Within Groups 180193.528 305 590.798   
Total 181174.919 307    
PCS   Between Groups 4513.256 2 2256.628 18.455 .000 
Within Groups 37294.300 305 122.276   
Total 41807.557 307    
MCS   Between Groups 76.515 2 38.258 .256 .774 
Within Groups 45524.474 305 149.261   
Total 45600.989 307    
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LSD test for the differences of QOL domains by participants' marital status  
Dependant 
variable 
(I) marital status (J) marital status Mean Difference           
(I-J) 
Std. Error Sig. 
PF 
MARRIED widow 11.5783766 6.7373567 .230 
single -33.9821758 * 6.2180710 .000 
widow married -11.5783766 6.7373567 .230 
single -45.5605524 * 8.7958534 .000 
RP 
married widow -8.48214 8.00332 .571 
single -39.37500 * 7.38646 .000 
widow married 8.48214 8.00332 .571 
single -30.89286 * 10.44861 .013 
BP 
married widow 12.470 7.261 .230 
single -20.713 * 6.701 .009 
widow married -12.470 7.261 .230 
single -33.183 * 9.478 .002 
SF 
married widow 2.3945 8.1401 .958 
single -19.7008 * 7.5127 .033 
widow married -2.3945 8.1401 .958 
single -22.0952 10.6271 .117 
RE 
married widow -1.062 7.771 .991 
single -18.061 * 7.172 .043 
widow married 1.062 7.771 .991 
single -16.999 10.144 .247 
PCS 
married widow 2.906 2.508 .512 
single -13.544 * 2.315 .000 
widow married -2.906 2.508 .512 
single -16.450 * 3.273 .000 
*The mean difference is significant at the 0.05 level. 
 
Level of education 
 
The averages, ANOVA and LSD test to assess the effect of education level on QoL 
domains 
QOL 
domain 
Level of education N Mean 
Std. 
Deviation 
PF 
No schooling 
 
110 46.55 30.99 
Elementary school and 
secondary 
160 61.84 29.13 
diploma 15 74.33 32.06 
university 26 83.27 20.69 
RP 
No schooling 
 
110 32.84 32.98 
Elementary school and 
secondary 
160 46.45 36.36 
diploma 15 70.42 36.02 
university 26 65.63 37.05 
BP 
No schooling 
 
109 43.31 32.24 
Elementary school and 
secondary 
160 48.36 32.06 
diploma 15 67.07 28.75 
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university 26 67.15 30.92 
GH 
No schooling 
 
110 43.35 21.13 
Elementary school and 
secondary 
160 49.81 22.24 
diploma 15 53.47 23.85 
university 26 57.58 18.77 
VT 
No schooling 
 
110 31.36 25.72 
Elementary school and 
secondary 
160 42.89 25.81 
diploma 15 58.75 25.20 
university 24 58.59 25.06 
SF 
No schooling 
 
110 57.50 38.47 
Elementary school and 
secondary 
160 67.50 34.63 
diploma 15 91.67 17.47 
university 26 73.56 34.52 
RE 
No schooling 
 
110 53.52 33.90 
Elementary school and 
secondary 
159 58.60 35.07 
diploma 15 75.56 31.26 
university 26 74.36 29.43 
MH 
No schooling 
 
110 46.32 23.90 
Elementary school and 
secondary 
160 57.63 23.50 
diploma 15 63.67 23.18 
university 24 61.88 23.49 
PCS 
No schooling 
 
110 37.93 10.81 
Elementary school and 
secondary 
160 41.91 11.55 
diploma 15 47.89 10.81 
university 24 50.26 10.20 
MCS 
No schooling 
 
110 38.17 11.85 
Elementary school and 
secondary 
160 42.18 12.37 
diploma 15 48.22 7.69 
university 24 45.78 10.90 
 
ANOVA 
 Sum of Squares Df Mean Square F Sig. 
PF    Between Groups 37186.968 3 12395.656 14.379 .000 
Within Groups 264653.157 307 862.062   
Total 301840.125 310    
RP    Between Groups 37232.718 3 12410.906 9.994 .000 
Within Groups 381232.414 307 1241.799   
Total 418465.133 310    
BP  Between Groups 17054.890 3 5684.963 5.590 .001 
Within Groups 311174.687 306 1016.911   
Total 328229.577 309    
GH  Between Groups 5700.549 3 1900.183 4.049 .008 
Within Groups 144061.946 307 469.257   
Total 149762.495 310    
VT    Between Groups 22925.950 3 7641.983 11.577 .000 
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Within Groups 201334.517 305 660.113   
Total 224260.467 308    
SF   Between Groups 19632.831 3 6544.277 5.204 .002 
Within Groups 386060.497 307 1257.526   
Total 405693.328 310    
RE    Between Groups 13568.997 3 4522.999 3.899 .009 
Within Groups 354947.259 306 1159.958   
Total 368516.256 309    
MH  Between Groups 11468.270 3 3822.757 6.847 .000 
Within Groups 170295.322 305 558.345   
Total 181763.592 308    
PCS   Between Groups 3877.059 3 1292.353 10.382 .000 
Within Groups 37965.439 305 124.477   
Total 41842.499 308    
MCS   Between Groups 2402.085 3 800.695 5.651 .001 
Within Groups 43213.880 305 141.685   
Total 45615.964 308    
 
LSD test for the differences of QOL domains by education level 
Dependent variable (I) level of education (J) level of education   
level 
Mean Difference (I-J) Std. Error Sig. 
PF 
No schooling 
Elementary and 
secondary 
-15.2972614 
*
 3.6365947 .001 
diploma -27.7879697 
*
 8.0813215 .009 
university -36.7238671 
*
 6.4025914 .000 
Elementary and 
secondary 
No schooling 15.2972614 
*
 3.6365947 .001 
diploma -12.4907083 7.9283489 .480 
University -21.4266058 
*
 6.2083924 .008 
diploma 
No schooling 27.7879697 
*
 8.0813215 .009 
Elementary and 
secondary 
12.4907083 7.9283489 .480 
universit  -8.9358974 9.5198253 .830 
RP 
No schooling 
Elementary and 
secondary 
-13.60440 
*
 4.36467 .022 
diploma -37.57576 
*
 9.69926 .002 
university -32.78409 
*
 7.68444 .001 
Elementary and 
secondary 
No schooling 13.60440
*
 4.36467 .022 
diploma -23.97135 9.51566 .098 
University -19.17969 7.45136 .087 
diploma 
No schooling 37.57576
*
 9.69926 .002 
Elementary and 
secondary 
23.97135 9.51566 .098 
Universit  4.79167 11.42577 .981 
BP 
No schooling 
Elementary and 
secondary 
-5.051 3.960 .654 
diploma -23.755 8.782 .065 
university -23.842 
*
 6.960 .009 
Elementary and 
No schooling 5.051 3.960 .654 
diploma -18.704 8.611 .196 
78 
 
secondary University -18.791 6.743 .053 
diploma 
No schooling 23.755 8.782 .065 
Elementary and 
secondary 
18.704 8.611 .196 
Universit  -.087- 10.340 1.000 
university 
No schooling 23.842 
*
 6.960 .009 
Elementary and 
secondary 
18.791 6.743 .053 
diploma .087 10.340 1.000 
GH 
No schooling 
Elementary and 
secondary 
-6.461 2.683 .124 
diploma -10.121 5.962 .412 
university -14.231 
*
 4.724 .030 
Elementary and 
secondary 
No schooling 6.461 2.683 .124 
diploma -3.660 5.850 .942 
university -7.771 4.581 .412 
diploma 
No schooling 10.121 5.962 .412 
Elementary and 
secondary 
3.660 5.850 .942 
universit  -4.110 7.024 .952 
VT 
No schooling 
Elementary and 
secondary 
-11.527 
*
 3.182 .005 
diploma -27.386 
*
 7.072 .002 
university -27.230 
*
 5.788 .000 
Elementary and 
secondary 
No schooling 11.527 
*
 3.182 .005 
diploma -15.859 6.938 .158 
university -15.703 5.624 .052 
diploma 
No schooling 27.386
 *
 7.072 .002 
Elementary and 
secondary 
15.859 6.938 .158 
universit  0.156 8.456 1.000 
university 
No schooling 27.230
 *
 5.788 .000 
Elementary and 
secondary 
15.703 5.624 .052 
diploma -.156 8.456 1.000 
SF 
No schooling 
Elementary and 
secondary 
-10.0000 4.3922 .161 
diploma -34.1667
*
 9.7605 .007 
university -16.0577 7.7329 .232 
Elementary and 
secondary 
No schooling 10.0000 4.3922 .161 
diploma -24.1667 9.5757 .097 
university -6.0577 7.4984 .884 
diploma 
No schooling 34.1667
 *
 9.7605 .007 
Elementary and 
secondary 
24.1667 9.5757 .097 
universit  18.1090 11.4979 .480 
RE 
No schooling 
Elementary and 
secondary 
-5.073 4.224 .696 
diploma -22.033 9.374 .140 
university -20.836 7.427 .051 
Elementary and 
secondary 
No schooling 5.073 4.224 .696 
diploma -16.960 9.199 .336 
university -15.763 7.205 .190 
diploma 
No schooling 22.033 9.374 .140 
Elementary and 
secondary 
16.960 9.199 .336 
universit  1.197 11.043 1.000 
MH No schooling 
Elementary and 
secondary 
-11.307 
*
 2.927 .002 
diploma -17.348 6.504 .070 
university -15.557 
*
 5.324 .038 
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Elementary and 
secondary 
No schooling 11.307 
*
 2.927 .002 
diploma -6.042 6.381 .826 
university -4.250 5.172 .879 
diploma 
No schooling 17.348 6.504 .070 
Elementary and 
secondary 
6.042 6.381 .826 
universit  1.792 7.777 .997 
PCS 
No schooling 
Elementary and 
secondary 
-3.975 
*
 1.382 .042 
diploma -9.955 
*
 3.071 .016 
university -12.323 
*
 2.514 .000 
Elementary and 
secondary 
No schooling 3.975
 *
 1.382 .042 
diploma -5.980 3.013 .270 
university -8.348 
*
 2.442 .009 
diploma 
No schooling 9.955 
*
 3.071 .016 
Elementary and 
secondary 
5.980 3.013 .270 
universit  -2.368 3.672 .937 
MCS 
No schooling 
Elementary and 
secondary 
-4.012 1.474 .062 
diploma -10.050 
*
 3.276 .026 
university -7.611 
*
 2.682 .047 
Elementary and 
secondary 
No schooling 4.012 1.474 .062 
diploma -6.037 3.214 .319 
university -3.598 2.606 .593 
diploma 
No schooling 10.050
*
 3.276 .026 
Elementary and 
secondary 
6.037 3.214 .319 
universit  2.439 3.918 .943 
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Occupation 
Averages, ANOVA and LSD tests to evaluate the effect of occupation on QOL domains 
QOL domain Current occupation N Mean Std. 
Deviation 
PF 
Full time job 47 80.85 20.83 
Part time job 17 75.29 23.35 
Not working 247 53.60 31.18 
RP 
Full time job 47 60.90 36.24 
Part time job 17 51.10 38.48 
Not working 247 40.60 35.88 
BP 
Full time job 47 62.83 31.00 
Part time job 17 61.12 33.65 
Not working 246 45.54 32.09 
GH 
Full time job 47 57.17 21.85 
Part time job 17 54.35 22.81 
Not working 247 46.19 21.56 
VT 
Full time job 47 51.20 25.63 
Part time job 17 47.43 18.50 
Not working 245 38.24 27.29 
SF 
Full time job 47 82.98 27.26 
Part time job 17 74.26 33.21 
Not working 247 61.69 36.95 
RE 
Full time job 46 73.19 31.08 
Part time job 17 61.76 31.74 
Not working 247 56.05 34.84 
MH 
Full time job 47 59.26 25.43 
Part time job 17 54.12 21.30 
Not working 245 53.30 24.28 
PCS 
Full time job 47 48.24 10.63 
Part time job 17 47.06 12.85 
Not working 245 39.71 11.21 
MCS 
Full time job 47 44.92 12.17 
Part time job 17 41.14 9.95 
Not working 245 40.64 12.26 
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ANOVA 
 Sum of Squares Df Mean Square F Sig. 
PF    Between Groups 34133.271 2 17066.635 19.633 .000 
Within Groups 266873.250 307 869.294   
Total 301006.520 309    
RP    Between Groups 17112.546 2 8556.273 6.575 .002 
Within Groups 399488.386 307 1301.265   
Total 416600.932 309    
BP  Between Groups 14420.508 2 7210.254 7.035 .001 
Within Groups 313641.285 306 1024.972   
Total 328061.793 308    
GH  Between Groups 5414.956 2 2707.478 5.766 .003 
Within Groups 144160.541 307 469.578   
Total 149575.497 309    
VT    Between Groups 7420.754 2 3710.377 5.225 .006 
Within Groups 216599.513 305 710.162   
Total 224020.267 307    
SF   Between Groups 19237.907 2 9618.953 7.643 .001 
Within Groups 386367.436 307 1258.526   
Total 405605.343 309    
RE    Between Groups 11533.429 2 5766.714 4.944 .008 
Within Groups 356922.854 306 1166.415   
Total 368456.283 308    
MH  Between Groups 1398.386 2 699.193 1.183 .308 
Within Groups 180279.861 305 591.082   
Total 181678.247 307    
PCS   Between Groups 3440.816 2 1720.408 13.672 .000 
Within Groups 38379.818 305 125.835   
Total 41820.634 307    
MCS   Between Groups 721.906 2 360.953 2.452 .088 
Within Groups 44890.998 305 147.184   
Total 45612.904 307    
 
QOL 
domains 
(I) job (J) job 
Mean Difference   (I-
J) 
Std. error Sig. 
PF 
1 
2 5.5565207 8.3444926 .801 
3 27.2537684
 *
 4.6935415 .000 
2 1 -5.5565207 8.3444926 .801 
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3 21.6972477 
*
 7.3938255 .014 
RP 
1 
2 9.80131 10.20938 .631 
3 20.30466
 *
 5.74249 .002 
2 
1 -9.80131 10.20938 .631 
3 10.50335 9.04625 .510 
BP 
1 
2 1.712 9.061 .982 
3 17.291
*
 5.098 .004 
2 
1 -1.712 9.061 .982 
3 15.579 8.030 .154 
GH 
1 
2 2.817 6.133 .900 
3 10.979 
*
 3.450 .007 
2 
1 -2.817 6.133 .900 
3 8.162 5.434 .325 
VT 
1 
2 3.770 7.542 .883 
3 12.954 
*
 4.245 .010 
2 
1 -3.770 7.542 .883 
3 9.184 6.685 .390 
SF 
1 
2 8.7140 10.0403 .686 
3 21.2917 
*
 5.6474 .001 
2 
1 -8.7140 10.0403 .686 
3 12.5777 8.8965 .369 
RE 
1 
2 11.424 9.694 .500 
3 17.142 
*
 5.486 .008 
2 
1 -11.424 9.694 .500 
3 5.718 8.565 .800 
PCS 
1 
2 1.181 3.175 .933 
3 8.531 
*
 1.787 .000 
2 
1 -1.181 3.175 .933 
3 7.350 
*
 2.814 .034 
*The mean difference is significant at the 0.05level, 1: full time job, 2: part time job and 3: 
unemployed.  
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Place of living 
Averages and ANOVA test to evaluate the effect of place of living on QOL domains  
QOL domains Place of living N Mean Std. Deviation 
PF 
Village 116 61.90 30.86 
city 190 56.58 31.32 
camp 4 83.75 22.87 
RP 
Village 116 49.57 36.47 
city 190 40.79 36.32 
camp 4 54.69 52.88 
BP 
Village 116 50.42 33.19 
city 189 47.71 32.23 
camp 4 70.75 34.85 
GH 
Village 116 47.16 22.89 
city 190 48.68 21.41 
camp 4 63.50 23.23 
VT 
Village 116 41.54 27.23 
city 188 39.56 26.50 
camp 4 71.88 32.87 
SF 
Village 116 69.40 34.94 
city 190 63.09 36.96 
camp 4 75.00 35.36 
RE 
Village 116 56.86 35.06 
city 189 59.83 34.39 
camp 4 75.00 31.92 
MH 
Village 116 52.80 22.16 
city 188 54.63 25.47 
camp 4 78.75 20.16 
PCS 
Village 116 42.95 11.82 
city 188 40.34 11.46 
camp 4 47.63 13.86 
MCS 
Village 116 40.46 11.90 
city 188 41.64 12.28 
camp 4 51.27 14.34 
 
ANOVA 
 Sum of Squares Df Mean Square F Sig. 
PF    Between Groups 4535.411 2 2267.705 2.348 .097 
Within Groups 296471.110 307 965.704   
Total 301006.520 309    
RP    Between Groups 5992.858 2 2996.429 2.240 .108 
Within Groups 410608.074 307 1337.486   
Total 416600.932 309    
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BP  Between Groups 2441.746 2 1220.873 1.147 .319 
Within Groups 325620.046 306 1064.118   
Total 328061.793 308    
GH  Between Groups 1104.237 2 552.119 1.142 .321 
Within Groups 148471.260 307 483.620   
Total 149575.497 309    
VT    Between Groups 4213.165 2 2106.582 2.923 .055 
Within Groups 219807.102 305 720.679   
Total 224020.267 307    
SF   Between Groups 3220.446 2 1610.223 1.229 .294 
Within Groups 402384.897 307 1310.700   
Total 405605.343 309    
RE    Between Groups 1683.625 2 841.812 .702 .496 
Within Groups 366772.658 306 1198.603   
Total 368456.283 308    
MH  Between Groups 2671.121 2 1335.560 2.276 .104 
Within Groups 179007.126 305 586.909   
Total 181678.247 307    
PCS   Between Groups 643.668 2 321.834 2.384 .094 
Within Groups 41176.965 305 135.006   
Total 41820.634 307    
MCS   Between Groups 500.971 2 250.486 1.694 .186 
Within Groups 45111.933 305 147.908   
Total 45612.904 307    
 
Number of family members 
 
QOL domain 
Pearson 
coefficient 
Sig. 
PF .033 .281 
RP .016 .389 
BP .056 .165 
GH -.005 .465 
VT -.005 .464 
SF .090 .057 
RE -.062 .141 
MH -.035 .274 
PCS .062 .141 
MCS -.037 .260 
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Monthly income 
Averages, ANOVA and LSD test to assess the effect of income on QOL domains 
QOL domains Monthly income N Mean Std. deviation 
PF    <3000 254 56.67 31.43 
3000-4000 40 71.37 26.43 
>4000 16 63.44 32.75 
RP    <3000 254 41.83 36.81 
3000-4000 40 53.44 34.41 
>4000 16 59.77 35.43 
BP  <3000 253 47.40 32.65 
3000-4000 40 56.85 32.08 
>4000 16 55.19 32.25 
GH  <3000 254 47.45 21.89 
3000-4000 40 50.63 23.95 
>4000 16 56.00 17.58 
VT    <3000 252 39.96 26.98 
3000-4000 40 44.06 26.96 
>4000 16 44.53 28.40 
SF   <3000 254 62.84 36.40 
3000-4000 40 83.13 28.10 
>4000 16 65.63 41.21 
RE    <3000 253 56.08 34.30 
3000-4000 40 74.17 31.74 
>4000 16 65.63 37.13 
MH  <3000 252 53.63 24.51 
3000-4000 40 58.00 22.67 
>4000 16 54.69 26.11 
PCS   <3000 252 40.73 11.80 
3000-4000 40 44.21 10.58 
>4000 16 45.27 11.07 
MCS   <3000 252 40.65 12.06 
3000-4000 40 45.40 10.95 
>4000 16 41.62 15.56 
 
ANOVA 
 Sum of Squares Df Mean Square F Sig. 
PF    Between Groups 7814.059 2 3907.029 4.091 .018 
Within Groups 293192.461 307 955.024   
Total 301006.520 309    
RP    Between Groups 8714.810 2 4357.405 3.280 .039 
Within Groups 407886.123 307 1328.619   
Total 416600.932 309    
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BP  Between Groups 3725.576 2 1862.788 1.757 .174 
Within Groups 324336.217 306 1059.922   
Total 328061.793 308    
GH  Between Groups 1347.189 2 673.594 1.395 .249 
Within Groups 148228.308 307 482.828   
Total 149575.497 309    
VT    Between Groups 826.628 2 413.314 .565 .569 
Within Groups 223193.638 305 731.782   
Total 224020.267 307    
SF   Between Groups 14213.610 2 7106.805 5.574 .004 
Within Groups 391391.732 307 1274.892   
Total 405605.343 309    
RE    Between Groups 12062.522 2 6031.261 5.178 .006 
Within Groups 356393.761 306 1164.685   
Total 368456.283 308    
MH  Between Groups 662.131 2 331.065 .558 .573 
Within Groups 181016.116 305 593.495   
Total 181678.247 307    
PCS   Between Groups 669.810 2 334.905 2.482 .085 
Within Groups 41150.823 305 134.921   
Total 41820.634 307    
MCS   Between Groups 778.421 2 389.211 2.648 .072 
Within Groups 44834.483 305 146.998   
Total 45612.904 307    
 
QOL 
dimension 
(I) income (j) income Mean Difference (I-J) Std. error Sig. 
PF 
<3000 3000-4000 -14.7019409
*
 5.2569521 .021 
>4000 -6.7649409 7.9654854 .698 
3000-4000 <3000 14.7019409
*
 5.2569521 .021 
>4000 7.9370000 9.1413690 .686 
RP 
<3000 3000-4000 -11.60679 6.20051 .175 
>4000 -17.93492 9.39518 .163 
3000-4000 <3000 11.60679 6.20051 .175 
>4000 -6.32813 10.78212 .842 
SF 
<3000 <3000 -20.2805
*
 6.0738 .004 
>4000 -2.7805 9.2033 .955 
3000-4000 <3000 20.2805
*
 6.0738 .004 
>4000 17.5000 10.5619 .255 
RE 
<3000 3000-4000 -18.090
*
 5.807 .008 
>4000 -9.548 8.798 .556 
3000-4000 <3000 18.090
*
 5.807 .008 
>4000 8.542 10.095 .699 
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Duration of diabetes 
Averages and ANOVA test to examine the effect of diabetes duration on QOL 
QOL domain 
Duration of diabetes 
(years) 
N Mean Std. Deviation 
PF 
0-5 52 69.13 30.30 
6-10 73 68.01 28.46 
11-60 185 52.46 30.98 
RP 
0-5 52 55.17 39.87 
6-10 73 48.29 37.13 
>10 185 39.59 34.96 
BP 
0-5 52 56.75 34.40 
6-10 73 53.07 32.18 
>10 184 45.24 31.90 
GH 
0-5 52 53.19 22.76 
6-10 73 49.03 21.47 
>10 185 46.64 21.89 
VT 
0-5 51 44.73 27.23 
6-10 73 41.87 27.98 
>10 184 39.16 26.57 
SF 
0-5 52 71.88 34.47 
6-10 73 70.38 35.81 
>10 185 61.96 36.60 
RE 
0-5 52 55.77 35.14 
6-10 73 66.10 33.14 
>10 184 56.95 34.78 
MH 
0-5 51 51.08 21.31 
6-10 73 55.14 25.33 
>10 184 54.78 24.75 
PCS 
0-5 51 46.76 13.06 
6-10 73 43.33 10.18 
>10 184 39.18 11.25 
MCS 
0-5 51 39.46 10.95 
6-10 73 42.27 12.35 
>10 184 41.46 12.46 
 
ANOVA 
 Sum of Squares Df Mean Square F Sig. 
PF    Between Groups 19187.071 2 9593.535 10.451 .000 
Within Groups 281819.449 307 917.979   
Total 301006.520 309    
RP    Between Groups 11398.414 2 5699.207 4.318 .014 
Within Groups 405202.519 307 1319.878   
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Total 416600.932 309    
BP  Between Groups 6933.907 2 3466.954 3.304 .038 
Within Groups 321127.886 306 1049.438   
Total 328061.793 308    
GH  Between Groups 1791.021 2 895.510 1.860 .157 
Within Groups 147784.476 307 481.383   
Total 149575.497 309    
VT    Between Groups 1361.437 2 680.718 .932 .395 
Within Groups 222658.830 305 730.029   
Total 224020.267 307    
SF   Between Groups 6165.069 2 3082.534 2.369 .095 
Within Groups 399440.274 307 1301.108   
Total 405605.343 309    
RE    Between Groups 4987.593 2 2493.797 2.099 .124 
Within Groups 363468.689 306 1187.806   
Total 368456.283 308    
MH  Between Groups 622.626 2 311.313 .524 .592 
Within Groups 181055.621 305 593.625   
Total 181678.247 307    
PCS   Between Groups 2643.812 2 1321.906 10.291 .000 
Within Groups 39176.822 305 128.449   
Total 41820.634 307    
MCS   Between Groups 245.897 2 122.949 .827 .439 
Within Groups 45367.007 305 148.744   
Total 45612.904 307    
 
 
Duration of using insulin 
Averages and ANOVA test to examine the effect of the duration of using insulin and QOL 
domains. 
QOL domain 
Duration of using insulin 
(years) 
N Mean 
PF 
0-5 184 58.97 
6-10 69 59.71 
11-60 55 56.27 
RP 
0-5 184 43.55 
6-10 69 44.38 
>10 55 44.43 
BP 0-5 183 49.43 
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6-10 69 46.58 
>10 55 48.91 
GH 
0-5 184 48.63 
6-10 69 45.39 
>10 55 50.07 
VT 
0-5 182 39.97 
6-10 69 41.21 
>10 55 41.59 
SF 
0-5 184 67.12 
6-10 69 64.49 
>10 55 60.68 
RE 
0-5 183 58.17 
6-10 69 65.22 
>10 55 52.58 
MH 
0-5 182 52.23 
6-10 69 57.25 
>10 55 56.64 
PCS 
0-5 182 41.70 
6-10 69 40.06 
>10 55 41.47 
MCS 
0-5 182 40.81 
6-10 69 43.12 
>10 55 40.48 
 
ANOVA 
 Sum of Squares Df Mean Square F Sig. 
PF    Between Groups 406.753 2 203.377 .209 .812 
Within Groups 297202.510 305 974.434   
Total 297609.263 307    
RP    Between Groups 54.736 2 27.368 .020 .980 
Within Groups 410290.612 305 1345.215   
Total 410345.348 307    
BP  Between Groups 409.107 2 204.554 .193 .825 
Within Groups 322422.111 304 1060.599   
Total 322831.218 306    
GH  Between Groups 770.870 2 385.435 .795 .452 
Within Groups 147807.013 305 484.613   
Total 148577.883 307    
VT    Between Groups 150.671 2 75.336 .103 .902 
Within Groups 221585.568 303 731.306   
Total 221736.239 305    
SF   Between Groups 1825.127 2 912.563 .693 .501 
Within Groups 401398.798 305 1316.062   
Total 403223.925 307    
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RE    Between Groups 5043.431 2 2521.716 2.120 .122 
Within Groups 361656.791 304 1189.660   
Total 366700.222 306    
MH  Between Groups 1675.782 2 837.891 1.415 .245 
Within Groups 179453.303 303 592.255   
Total 181129.085 305    
PCS   Between Groups 136.638 2 68.319 .506 .604 
Within Groups 40931.212 303 135.087   
Total 41067.850 305    
MCS   Between Groups 310.172 2 155.086 1.041 .354 
Within Groups 45124.790 303 148.927   
Total 45434.962 305    
 
 
Type of diabetes 
T-test to assess the relationship between QOL and diabetes type. 
QOL domain 
Type of 
diabetes 
N Mean 
Std. 
Deviation 
T df 
Sig. (2-
tailed) 
PF 
1 269 54.720520 30.0246501 -6.453 308 .000 
2 41 86.463171 24.2705194    
RP 
1 269 40.0325 35.49283 -5.418 308 .000 
2 41 71.9512 32.68941    
BP 
1 268 45.92 32.135 -4.400 307 .000 
2 41 69.32 28.672    
GH 
1 269 46.13 20.892 -4.597 308 .000 
2 41 62.56 23.977    
VT 
1 267 38.04 26.112 -4.601 306 .000 
2 41 58.23 26.533    
SF 
1 269 62.965 36.5842 -3.340 308 .001 
2 41 82.927 28.6078    
RE 
1 268 57.98 34.948 -1.219 307 .224 
2 41 65.04 31.854    
MH 
1 267 53.28 24.187 -1.804 306 .072 
2 41 60.61 24.576    
PCS 1 267 39.69 10.907 -7.126 306 .000 
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2 41 52.63 10.280    
MCS 
1 267 41.02 12.237 -1.085 306 .279 
2 41 43.24 11.842    
 
HbA1c level 
T-test to examine the effect of HbA1c level on QOL domains 
QOL domain HbA1c level N Mean Std. Deviation 
t df Sig. (2-tailed) 
PF 
<7 8 71.25 35.93 1.077 260 .282 
>7 254 59.25 30.86    
RP 
<7 8 58.59 39.38 1.124 260 .262 
>7 254 43.92 36.25    
BP 
<7 8 49.75 37.48 .068 259 .946 
>7 253 48.97 31.64    
GH 
<7 8 62.63 20.71 1.957 260 .051 
>7 254 47.50 21.55    
VT 
<7 7 39.29 35.49 -.120 258 .904 
>7 253 40.51 26.38    
SF 
<7 8 57.81 48.61 -.662 260 .509 
>7 254 66.54 36.32    
RE 
<7 8 73.96 30.03 1.228 259 .220 
>7 253 58.51 35.14    
MH 
<7 7 60.71 15.92 .684 258 .495 
>7 253 54.39 24.30    
PCS 
<7 7 45.59 14.95 .976 258 .330 
>7 253 41.34 11.27    
MCS 
<7 7 44.38 8.94 .663 258 .508 
>7 253 41.32 12.12    
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Number of insulin types 
T-test to examine the effect of the number of insulin types the patient use and QoL 
QOL 
domains 
Number of insulin 
types used 
N Mean 
Std. 
Deviation 
t df Sig. (2-tailed) 
PF 
1 type 222 56.17 31.12 -3.226 280 .001 
2 type 60 70.67 29.98    
RP 
1 type 222 42.17 36.20 -2.300 280 .022 
2 type 60 54.27 35.94    
BP 
1 type 221 47.83 32.41 -1.099 279 .273 
2 type 60 53.02 32.48    
GH 
1 type 222 47.27 22.66 -1.175 280 .241 
2 type 60 51.03 19.22    
VT 
1 type 221 40.19 27.17 -.661 278 .509 
2 type 59 42.80 26.00    
SF 
1 type 222 63.68 36.58 -1.314 280 .190 
2 type 60 70.63 35.34    
RE 
1 type 221 58.01 35.66 -1.305 279 .193 
2 type 60 64.58 30.17    
MH 
1 type 221 53.71 24.97 -.220 278 .826 
2 type 59 54.49 21.25    
PCS 
1 type 221 40.56 11.29 -2.629 278 .009 
2 type 59 45.00 12.32    
MCS 
1 type 221 41.12 12.59 -.295 278 .768 
2 type 59 41.64 10.40    
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Insulin regimen 
Averages and ANOVA test to examine the effect of insulin regimen on QOL. 
QOL 
domain 
regimen N Mean Std. Deviation 
PF 
once 30 55.33 34.01 
twice 209 58.71 30.45 
Three times 71 61.06 32.48 
RP 
once 30 40.83 34.65 
twice 209 42.17 36.99 
Three times 71 51.85 36.20 
BP 
once 30 52.90 34.16 
twice 208 47.92 32.12 
Three times 71 50.62 33.75 
GH 
once 30 56.40 17.87 
twice 209 46.15 22.07 
Three times 71 51.23 22.50 
VT 
once 30 42.92 25.68 
twice 208 39.39 27.32 
Three times 70 43.75 26.73 
SF 
once 30 72.08 34.85 
twice 209 63.70 36.96 
Three times 71 68.49 34.58 
RE 
once 29 65.23 33.26 
twice 209 56.18 34.98 
Three times 71 64.38 33.42 
MH 
once 30 57.33 24.63 
twice 208 54.06 24.89 
Three times 70 53.50 22.69 
PCS 
once 30 40.95 11.84 
twice 208 40.96 11.45 
Three times 70 42.96 12.28 
MCS 
once 30 44.49 12.13 
twice 208 40.55 12.52 
Three times 70 42.26 11.05 
 
ANOVA 
 Sum of Squares Df Mean Square F Sig. 
PF    Between Groups 719.474 2 359.737 .368 .693 
Within Groups 300287.047 307 978.134   
Total 301006.520 309    
RP    Between Groups 5358.151 2 2679.075 2.000 .137 
Within Groups 411242.782 307 1339.553   
Total 416600.932 309    
BP  Between Groups 883.591 2 441.796 .413 .662 
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Within Groups 327178.202 306 1069.210   
Total 328061.793 308    
GH  Between Groups 3543.500 2 1771.750 3.725 .025 
Within Groups 146031.996 307 475.674   
Total 149575.497 309    
VT    Between Groups 1153.668 2 576.834 .789 .455 
Within Groups 222866.599 305 730.710   
Total 224020.267 307    
SF   Between Groups 2609.858 2 1304.929 .994 .371 
Within Groups 402995.485 307 1312.689   
Total 405605.343 309    
RE    Between Groups 4838.016 2 2419.008 2.036 .132 
Within Groups 363618.267 306 1188.295   
Total 368456.283 308    
MH  Between Groups 331.893 2 165.946 .279 .757 
Within Groups 181346.354 305 594.578   
Total 181678.247 307    
PCS   Between Groups 217.123 2 108.562 .796 .452 
Within Groups 41603.510 305 136.405   
Total 41820.634 307    
MCS   Between Groups 486.970 2 243.485 1.646 .195 
Within Groups 45125.934 305 147.954   
Total 45612.904 307    
 
Patients' choice to use insulin pens or syringes 
T-test to assess the relationship between patient's choice and QOL. 
QOL domain     Choice 
pen/syringe N Mean Std. Deviation 
t df Sig. (2-tailed) 
PF    pens 
180 62.64 30.09 2.489 308 .013 
syringe 
130 53.77 32.11       
RP    pens 
180 46.88 35.04 1.482 308 .139 
syringe 
130 40.63 38.77       
BP  pens 
180 49.25 31.76 .142 307 .887 
syringe 
129 48.71 33.95       
GH  pens 
180 47.82 21.72 -.452 308 .651 
syringe 
130 48.97 22.46       
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VT    pens 
179 41.86 27.07 .871 306 .385 
syringe 
129 39.15 26.96       
SF   pens 
180 66.39 34.79 .448 308 .655 
syringe 
130 64.52 38.25       
RE    pens 
179 57.22 33.37 -1.012 307 .312 
syringe 
130 61.25 36.19       
MH  pens 
179 53.52 24.67 -.623 306 .534 
syringe 
129 55.27 23.90       
PCS   pens 
179 42.55 11.22 2.010 306 .045 
syringe 
129 39.85 12.15       
MCS   pens 
179 40.58 12.16 -1.246 306 .214 
syringe 
129 42.34 12.20    
 
 
Diabetes complications: 
Averages and ANOVA test to examine the effect of diabetes complications on QOL 
domains. 
QOL domain 
Number of 
complications 
N Mean 
PF 
0 71 77.61 
1.00 67 72.16 
2.00 74 57.29 
3.00 54 41.67 
4.00 28 34.82 
5-7 16 28.44 
RP 
0 71 63.56 
1.00 67 59.61 
2.00 74 41.55 
3.00 54 28.94 
4.00 28 11.38 
5-7 16 16.02 
BP 
0 71 62.35 
1.00 67 57.55 
2.00 73 48.64 
3.00 54 34.15 
4.00 28 37.54 
5-7 16 26.25 
GH 0 71 61.10 
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1.00 67 51.82 
2.00 74 48.59 
3.00 54 37.85 
4.00 28 38.71 
5-7 16 27.50 
VT 
0 70 54.82 
1.00 66 43.84 
2.00 74 42.65 
3.00 54 27.66 
4.00 28 29.91 
5-7 16 20.31 
SF 
0 71 77.29 
1.00 67 75.00 
2.00 74 68.92 
3.00 54 51.85 
4.00 28 47.32 
5-7 16 37.50 
RE 
0 71 71.13 
1.00 66 60.80 
2.00 74 58.22 
3.00 54 52.78 
4.00 28 52.08 
5-7 16 32.81 
MH 
0 70 61.43 
1.00 66 52.27 
2.00 74 59.46 
3.00 54 48.61 
4.00 28 48.39 
5-7 16 36.25 
PCS 
0 70 48.56 
1.00 66 47.14 
2.00 74 40.32 
3.00 54 34.55 
4.00 28 31.88 
5-7 16 31.50 
MCS 
0 70 45.17 
1.00 66 40.42 
2.00 74 43.27 
3.00 54 38.61 
4.00 28 39.43 
5-7 16 31.61 
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ANOVA 
 Sum of Squares Df Mean Square F Sig. 
PF    Between Groups 83938.853 5 16787.771 23.511 .000 
Within Groups 217067.668 304 714.038   
Total 301006.520 309    
RP    Between Groups 98470.829 5 19694.166 18.819 .000 
Within Groups 318130.103 304 1046.481   
Total 416600.932 309    
BP  Between Groups 41439.510 5 8287.902 8.761 .000 
Within Groups 286622.283 303 945.948   
Total 328061.793 308    
GH  Between Groups 27856.969 5 5571.394 13.915 .000 
Within Groups 121718.528 304 400.390   
Total 149575.497 309    
VT    Between Groups 33982.692 5 6796.538 10.801 .000 
Within Groups 190037.575 302 629.263   
Total 224020.267 307    
SF   Between Groups 48631.076 5 9726.215 8.283 .000 
Within Groups 356974.266 304 1174.257   
Total 405605.343 309    
RE    Between Groups 25098.278 5 5019.656 4.430 .001 
Within Groups 343358.005 303 1133.195   
Total 368456.283 308    
MH  Between Groups 13735.123 5 2747.025 4.940 .000 
Within Groups 167943.124 302 556.103   
Total 181678.247 307    
PCS   Between Groups 12488.870 5 2497.774 25.717 .000 
Within Groups 29331.764 302 97.125   
Total 41820.634 307    
MCS   Between Groups 3376.052 5 675.210 4.828 .000 
Within Groups 42236.852 302 139.857   
Total 45612.904 307    
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Appendix G 
 
Quality metric health outcome scoring software results of norm based scoring. 
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 تقييم لاستخدام الانسولين في وزارة الصحة الفمسطينية ومضاعفات مرض السكري
 جمعة مدمحمد اح عداد: سممىإ
 شراف: د. حسين حلاقإ
 الممخص
ىؤلاء المرضى بحاجة للالتزام بالادوية والحمية الغذائية و  عداد مرضى السكري في ازدياد حول العالمأ
نوعية  مما يؤثر عمى والزيارات الدورية للاطباء وذلك لموصول الى المستوى الطبيعي لمسكر في الدم 
. مع تطور المرض  يحتاج المرضى لاستخدام ةونفسي ةماعي, اجتةمن عدة نواحي: جسدي يمالحياة ل
% من الفمسطينيين مصابون بالسكري. 12الانسولين. حسب احصائيات وزارة الصحة الفمسطينية 
% يستخدمون علاج 12% من مراجعي عيادات الصحة يستخدمون علاج الانسولين بينما 21
الانسولين في حين خيار الاقلام غير متوفر. الاقراص والانسولين. وزارة الصحة توفر الابر لحقن 
معظم دراسات نوعية الحياة لمرضى السكري تمت في الدول المتقدمة وعدد قميل منيا في الدول 
 النامية.
اليدف من ىذه الدراسة كان لتقييم نوعية حياة مرضى السكري المستخدمين للانسولين : هدف الدراسة
 والعوامل المؤثرة عمييا.   
مريض سكري يستخدون  221اجريت ىذه الدراسة عمى عينة عشوائية تتكون من : ت الدراسةاجراءا
سنة ويتمقون العلاج في عيادات السكري التابعة لوزارة  12الابر لحقن الانسولين واعمارىم اكبر من 
الصحة في محافظتي بيت لحم والخميل. الاستبيان المستخدم في الدراسة كان يشمل اربع اجزاء: 
مومات ديموغرافية عن المرضى, معمومات المريض الصحية, نوعية الحياة لممرضى, استعداد مع
 001
 
المرضى لدفع مبمغ من المال مقابل استحدام اقلام الانسولين. تم الحصول عمى موافقة وزارة الصحة 
امج لعمل الدراسة وموافقة المريض الشفيية قبل تعبئة الاستمارة. تم تحميل النتائج باستخدام برن
 .SSPSوكذلك برنامج  0.4 erawtfoS gnirocS ™semoctuO htlaeH cirteMytilauQ
 النتائج والتوصيات
. اعمى قيمة كانت لممجال الذي يقيم الحالة 6..6الى  4.21تراوحت متوسطات قيم نوعية الحياة من 
. اقل القيم كانت لممجال 5...يمييا الصحة الجسدية والنفسية  بمعدل  6..6الاجتماعية بمعدل 
دا المجال . كانت معدلات نوعية الحياة في جميع المجالات ,ع4.21المتعمق بالحيوية والطاقة بمعدل 
الاجتماعي, لمرضى السكري في ىذه الدراسة اقل من المعدلات العامة لمسكان في فمسطين. وقد كانت 
 نوعية الحياة لمعظم المرضى في ىذه الدراسة اقل من المعدل العام. 
لقد اوضحت النتائج ان الجنس والعمر والتحكم بمستوى السكر في الدم لا يؤثر عمى نوعية الحياة 
. نوعية الحياة لممرضى غير المتوزجين كانت افضل من المتزوجين, نوعية الحياة لمرضى لممرضى
السكري في بيت لحم كانت افضل من المرضى سكان الخميل. زيادة المستوى التعميمي, الدخل الشيري 
 وكون المريض يعمل كان ليا اثر ايجابي عمى نوعية الحياة. في حين كانت نوعية الحياة اقل لممرضى
المذين يعانون من السكري لفترة اطول. وجود مضاعفات السكري كانت ليا تأثير سمبي عمى نوعية 
الحياة لممرضى. نوعية الحياة لممرضى المذين يعانون من النوع الثاني كانت افضل منيا لمرضى النوع 
ر اذا وفرتو % من المرضى في ىذه الدراسة فضمو استخدام اقلام الانسولين بدلا من الاب.. الاول.
% من ىؤلاء المرضى كان لدييم الاستعداد لدفع مبمغ من المال مقابل الحصول .1وزارة الصحة. 
 عمى الاقلام.
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اوضحت ىذه الدراسة ان نوعية الحياة لمرضى السكري المذين يستخدمون الانسولين كانت متدنية. 
بر يزيد من نوعية الحياة, فاضافة كثير من الدراسات اوضحت ان استخدام اقلام الانسولين بدلا من الا
اقلام الانسولين كخيار لممرضى المذين يتمقون العلاج في عيادات وزارة الصحة قد يزيد من نوعية 
 الحياة ليم.    
 
 
 
